GENES AND PROTEINS PREDICTIVE AND THERAPEUTIC FOR STROKE, HYPERTENSION, DIABETES AND OBESITY

Abstract: The present invention discloses genes whose expression is modulated in SHR-rats, which is an animal model for human metabolic X syndrome. Also disclosed are genes whose gene products are altered in SHR animals compared to control animals. The invention further discloses methods of diagnosing or treating conditions associated with metabolic X syndrome using these genes and gene products.

Description: GENES AND PROTEINS PREDICTIVE AND THERAPEUTIC FOR STROKE, HYPERTENSION, DIABETES AND OBESITY FIELD OF THE INVENTION The present invention relates to nucleic acids and polypeptides and to methods of using the same. In particular, the invention relates to nucleic acids and polypeptides whose expression is modulated in animals having metabolic syndrome X-related syndromes, and methods of using the same. RELATED APPLICATIONS This application claims priority to United States Application Serial Number 09/161,939 filed September 28, 1998, which is incorporated herein by reference in its entirety. BACKGROUND OF THE INVENTION Human Metabolic Syndrome X is a relatively common but poorly understood disorder with multiple manifestations. Individuals suffering from Metabolic Syndrome X can exhibit, e.g., hypertension, insulin resistance, dyslipidemia and abdominal obesity. A recognized model of human Metabolic Syndrome X is the spontaneously hypertensive rat (SHR), which is characterized by salt-induced hypertension, insulin resistance and increased abdominal fat. A spontaneous variant of SHR, named SHR stoke-prone (SHR-SP), additionally undergoes severe hemorrhage or ischemic stroke. The gene or genes influencing the manifestation and latency period of stroke within SHR animals, or of metabolic X syndrome, have not been identified. SUMMARY OF THE INVENTION The invention is based in part on the identification of a set of genes whose expression is differentially regulated in SHR animals compared to control animals. These genes include (.) CD36 (also known as fatty acid transport protein (FAT)); (ii) sodium dependent glucose co- transporter (SGLT2); (iii) aldolase A; (iv) kynurenine aminotransferase; (v) α-cardiac myosin and (vi) α-tubulin; and (vi) atrial natriuretic peptide (ANP). These genes will be referred to collectively herein as the "GENE SET". The invention is also based in part on the discovery that some genes whose expression is altered in SHR animals encode altered gene products relative to the analogous gene products in control animals. These genes include CD36, SLGT2, aldolase A, kynuerenine aminotransferase, and ANP. The present invention discloses the use of genes within a GENE SET, or mutations of the genes within the GENE SET, as diagnostics and therapeutics for disease. The present invention discloses isolated proteins, protein derivatives, analogs and mutations thereof, for use in the diagnosis, prognosis and screening, as well as the treatment, both prophylactic and therapeutic, of diseases such as hypertension, diabetes (insulin resistance), obesity/dyslipidemia and stroke (ischemic disease). Further disclosed herein are methodologies of diagnosis, prognosis, and screening by detecting genes from the GENE SET. Diagnostic, prognostic and screening kits are also provided. Additionally, the present invention also discloses methods of screening for modulators of GENE SET activity which affect hypertension, diabetes, obesity and both the latency period and severity of stroke. BRIEF DESCRIPTION OF THE FIGURES FIG. 1 is an illustration of GeneCalling ® chromatograms of 3 fragments of 3-β- hydroxysteroid dehydrogenase/Δ-5-Δ-4 isomerase cDNA. Hsdb3 mRNA was increased in abundance 85-fold in SHR kidney. Using 66 GeneCalling ® reactions, 10 cDNA fragments derived from Hsdb3 were assayed. Restriction enzyme pairs, cDNA fragment lengths, and fragment locations within Hsdb3 cDNA are indicated. Differentially expressed peaks are indicated by vertical lines. The 3 traces in each panel represent 3 animals sampled from each strain. Each trace represents the composite of 2 or 3 replicate experiments with each sample. FIG. 2 is an illustration of the differential-expression of selected genes. GeneCalling ® chromatograms showing differential expression of Kat, Sglt2, Cd36, Aldoa, and Anf in SHR, SHRSP, and WKY rats. (Panel A) Kαt increased 22-fold in SHR kidney. (Panel B) Sglt2 decreased 6.7-fold in SHR kidney. (Panel C) Cd36 decreased 21 -fold in SHR fat. (Panel D) Aldoα decreased 52-fold in SHRSP heart. (Panel E) 2-bp deletion in 3' UTR of Anf in SHRSP heart cDNA causes shift of peak from 172-bp to 170-bp. (Panel F) Anf increased 2.3-fold in SHRSP heart. Differentially expressed gene fragments are indicated by red vertical lines. The 3 traces in each panel represent 3 animals sampled from each strain. Each trace represents the composite of 2 or 3 replicate experiments with each sample. In Panel E, the GeneCalling ® reaction identified a two base-pair deletion in the untranslated region of prepronatriodilatin which accounts for the shift of the peak from 172 to 170. The vertical line indicates the peak of the expression difference. Fragment length in nucleotides is indicated on the x-axis, and relative peak intensity is indicated on the y-axis. Each trace represents the composite of multiple reactions from a single animal. FIG. 3 is an illustration of rat radiation hybrid mapping of differentially expressed candidate genes: (Panel A) SGLT2 (right of map) relative to 3 independent chromosome 1 linkage studies (left of map). Regions of maximum likelihood are denoted by a vertical bar. (Panel B) KAT (ή i of map) relative to 1 linkage. FIG. 4 is an illustration of the species and strain variations of amino acid residues in selected genes. The predicted amino acid residue variation, based on nucleotide changes found in cDNAs encoding the proteins shown, are indicated by underlining. The first and last amino acids are numbered relative to the start of translation, as indicted in the corresponding GenBank entry. The amino acid sequences are shown as (Panel A) SGLT2 [SEQ ID NOs:l -5], (Panel B) kynurenine aminotransferase [SEQ ID NOs:6-9], (Panel C) CD36/FAT [SEQ ID NOs:10-13 and 14-17], (Panel D) aldolase A [SEQ ID NOs:18-25], (Panel E) prepronatriodilatin [SEQ ID NOs:26-31], (Panel F) α-cardiac myosin [SEQ ID NOs:32-36], and (Panel G) α-tubulin [SEQ ID NOs:37-42]. DETAILED DESCRIPTION OF THE INVENTION The present invention discloses a GENE SET comprising a total of 6 genes which were found to be both differentially-expressed and mutated (i.e., possessing amino acid residue substitutions) between disease and control states in genetic rat models of hypertension, obesity, diabetes and stroke. The GENE SET (hereinafter "GENE SET") includes: ( ) CD36 (also known as fatty acid transport protein (FAT)); ( ) sodium dependent glucose co-transporter (SGLT2); (iii) aldolase A; (iv) kynurenine aminotransferase; (v) α-cardiac myosin and (vi) α-tubulin; as well as the previously-described mutation in the atrial natriuretic peptide (ANP). In order to identify the primary genetic defects leading to the phenotype of the SHR and SHR-SP, the present invention has included a comprehensive gene expression analysis utilizing the GeneCalling ® technology (as described in, e.g., U.S. Patent No. 5871,697) to identify the majority of differentially-expressed genes between the strains of animals that were used for genetic linkage analysis. GeneCalling ® not only identifies both known and novel differentially- expressed genes, but also identifies sequence variations in complementary DNA (cDNA) between the various strains being compared. These variations detected by GeneCalling ® can include, but are not limited to, insertions, deletions and single base-pair changes. Accordingly, the present invention relates to mutants of the proteins which are encoded by aforementioned GENE SET (and derivatives, fragments and homologs thereof) and the nucleic acids which encode them (and derivatives, fragments and homologs thereof), which function so as to increase predisposition to stroke, hypertension, diabetes and obesity. The present invention relates to methods of diagnosis, prognosis and screening for stroke, hypertension, diabetes and obesity. In one embodiment, subjects are screened for a mutant allele of the GENE SET. In another embodiment, subjects are screened to differentiate the expression of mRNAs derived from the GENE SET, relative to their expression within controls. The present invention also relates to methods of screening members of the GENE SET for the ability to affect the onset of, or predisposition to, hypertension, diabetes (insulin resistance) or obesity (dyslipidemia) or stroke, and to methodologies of screening for modulators (i.e., agonists, antagonists and inhibitors) of these genes. (1) Mutated GENE SET Proteins produced from the GENE SET, and mutants of derivatives, fragments, homologs and analogs of GENE SET proteins and the nucleic acids encoding the mutants, protein derivatives and protein analogs are disclosed by the present invention. The GENE SET mutants can be proteins possessing substitutions, deletions or insertions of one or more amino acid residues within the amino acid sequence wild-type GENE SET protein. Preferably, the GENE SET mutants are capable of binding to an anti-GENE SET antibody. In another embodiment of the present invention, the GENE SET mutant increases latency to hypertension or stroke in stroke-prone rats (e.g., rats possessing the stroke-predisposing locus located on chromosome 1) which are fed a high salt diet (for example, but not limited to, a diet of 17.5% protein, 3.7 mg/g body weight Na + , 6.3 mg/kg body weight K\ and 0.03 mg/g body weight methionine and 1% NaCl drinking water). Derivatives or analogs of GENE SET include, but are not limited to, those molecules comprising regions which are substantially homologous to the wild-type GENE SET or mutant GENE SET, or fragments thereof. For example, in various embodiments, at least 60-70% homology, preferably 70-80% homology, more preferably 90-95% homology and most preferably > 95% homology over an amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is performed by a computer homology program known within the art, or whose encoding nucleic acid is capable of hybridizing to a coding GENE SET sequence, under stringent, moderately stringent, or non-stringent conditions. In some embodiments, the isolated protein is a member of the GENE SET which includes one or more of the amino acid substitutions in the SHR or SHR-SP proteins as indicated in FIGS. 5A-G. Thus, the invention includes an isolated protein having the L638Q mutation, e.g., an isolated protein having the amino acid sequence motif RQE and which has at least 60-70% homology, preferably 70-80% homology, more preferably 90-95% homology and most preferably > 95% homology to a rat or human SGLT2 sequence. The protein may optionally include one, two. three, four, or five or more additional amino acids flanking, (i.e., on the amino or carboxy terminus) the regions corresponding to the RQE sequence shown in FIG. 4. Thus, the protein can optionally include, e.g, the amino acids RRQE, RQED, RRQED, TRRQED, RRQEDI, etc. Also included is an isolated protein which has at least 60-70% homology, preferably 70- 80% homology, more preferably 90-95% homology and most preferably > 95% homology to a rat or human kynurenine aminotransferase sequence, and which includes the amino acid sequence substitution E27G, as is indicated in FIG. 4E. The invention further includes an isolated protein which includes the amino acid sequence IVE and which has at least 60-70% homology, preferably 70-80% homology, more preferably 90-95% homology and most preferably > 95% homology to a rat or human aldolase A sequence. The protein may optionally include one, two, three, four, or five or more additional amino acids derived from the rat or human aldolase sequence on the amino or carboxy terminus of the IVE sequence, as shown in FIG. 4. To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch 1970 J Mol Biol 48: 443- 453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%. The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) or amino acid occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide or polypeptide sequence, wherein the polypeptide or polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region. Also included is an isolated protein having the amino acid sequence motif RSI and which which has at least 60-70% homology, preferably 70-80% homology, more preferably 90-95% homology and most preferably > 95% homology to a rat or human alpha tubulin sequence. The protein may optionally include one, two, three, four, or five or more additional amino acids derived from the rat or human aldolase sequence on the amino or carboxy terminus of the RSI sequence, as shown in FIG. 4. The invention also includes alpha tubulins having the S340T amino acid substitution. The GENE SET, as well as fragments, derivatives, homologs and analogs GENE SET, of the present invention can be produced by various methods known within the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned GENE SET gene sequence can be modified by any of numerous strategies known within the art. See e.g., Sambrook, et al, 1990. Molecular Cloning, A Laboratory Manual, 2d ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). The sequence of interest may be cleaved at appropriate sites with a restriction endonuclease (RE), followed by further enzymatic modification (if necessary), isolated, and ligated in vitro. In the production of the gene encoding a mutant, derivative or analog of the GENE SET, care should be taken to ensure that the modified gene remains within the same translational reading frame as the GENE SET and is uninterrupted by translational stop signals within the exonic region where the desired GENE SET activity is encoded. The GENE SET-encoding nucleic acid sequence may be mutated in vitro or in vivo, to make changes within the coding regions (e.g., amino acid substitutions, additions or deletions) as well as to create and/or destroy translation, initiation, and/or termination sequences, or to form new restriction endonuclease sites or destroy pre-existing ones, to facilitate further in vitro modification. Any technique for mutagenesis known within the art may be utilized including, but not limited to, chemical mutagenesis; in vitro site-directed mutagenesis (see e.g., Hutchinson, et al., 1978. J. Biol. Chem. 253:6551); use of TAB7 ® linkers (Pharmacia), and the like. Manipulations of the GENE SET sequence may also be made at the protein level. Included within the scope of the invention are GENE SET protein fragments or other derivatives or analogs which are differentially-modified during or after translation (e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc). Any of numerous chemical modifications may be performed by known techniques, including but not limited to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH 4 ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc. Particularly included within the scope of the present invention are those modifications which reduce the level or activity of the GENE SET. In addition, mutant GENE SET proteins (or analogs and derivatives thereof) which mediate the desired activity in vivo or in vitro, may be synthesized by use of a peptide synthesizer. Furthermore, if desired, non-classical amino acids or chemical amino acid analogs may be introduced as a substitution or addition into the GENE SET sequence. Non-classical amino acids include, but are not limited to: the D-isomers of the common amino acids, α-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, γ-Abu, ε-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3 -amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β-alanine. fluoro-amino acids, designer amino acids such as β-methyl amino acids, Cα-methyl amino acids, Nα-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid may either be D (dextrorotary) or L (levorotary) isomers. In another embodiment of the present invention, the GENE SET derivative is a chimeric, or fusion, protein comprising an GENE SET protein or fragment thereof (preferably consisting of at least 10 amino acids of the GENE SET protein or a mutant GENE SET protein) joined at its amino- or carboxyl-terminus via a peptide bond to an amino acid sequence of a different protein. In one embodiment, such a chimeric protein is produced by recombinant expression of a nucleic acid encoding the protein (i.e., comprising a GENE SET-coding sequence joined in-frame to a coding sequence for a different protein). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques (e.g., by use of a peptide synthesizer). Chimeric genes comprising portions of the wild-type GENE SET or the mutant GENE SET fused to any heterologous protein-encoding sequences may be constructed. A specific embodiment of the present invention discloses a chimeric protein comprising a fragment of GENE SET or mutant GENE SET of at least six amino acids. Additionally, due to the degeneracy of nucleotide-coding sequences, other DNA sequences which encode substantially the same amino acid sequence as the mutant GENE SET of the present invention may be utilized in the practice of the present invention. The genes indigenous to the mutant GENE SET may be obtained by alteration of nucleotide sequences comprising all or portions of GENE SET gene by the substitution of different codons which encode the desired amino acid. For example, one or more amino acid residues within the sequence may be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a "silent alteration." Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include, but are not limited to, alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include, but are not limited to, glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include, but are not limited to, arginine, lysine and histidine. The negatively charged (acidic) amino acids include, but are not limited to, aspartic acid and glutamic acid. In addition, the present invention discloses mutant GENE SET molecules, containing the aforementioned mutations for mutant GENE SET molecules. (2) Nucleic Acid Sequences and Proteins of the GENE SET GENE SET proteins and nucleic acids can be obtained by any methodology known within the art. The GENE SET amino acid and nucleotide sequences for, inter alia, human, rat, hamster, dog, mouse, bovine, porcine, equine, dogfish, Drosophila melanogaster and Xenopus are available in the public databases (e.g., GenBank). Any eukaryotic cell potentially can serve as the nucleic acid source for the isolation of GENE SET nucleic acids. The nucleic acid sequences of the GENE SET may be isolated from vertebrate, mammalian, human, porcine, bovine, feline, avian, equine, canine, primate, and like sources. The DNA may be obtained by standard protocols known within the art from cloned DNA (e.g., a DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA (or fragments thereof) purified from the desired cell. See e.g., Sambrook, et al., 1990. Molecular Cloning, A Laboratory Manual, 2d ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY); Glover, 1985. DNA Cloning: A Practical Approach (MRL Press, Ltd., Oxford, U.K.). Clones which are derived from genomic DNA may contain regulatory and non- coding, intron DNA regions, in addition to coding, exonic regions; whereas clones which are derived from cDNA will contain only coding, exon sequences. -Following isolation, the sequence of interest is then molecularly-cloned into a suitable vector for propagation. In the molecular cloning of the gene from complementary DNA (cDNA), the cDNA is synthesized by reverse transcription from total cellular RNA or poly(A) + mRNA by methods which are well-known within the art. The gene(s) of interest may also be obtained from genomic DNA, wherein random DNA fragments are generated (e.g., by use of restriction endonucleases or by mechanical shearing), some of which will encode the desired sequence(s). The linear DNA fragments may then be separated as a function of their size by standard techniques including, but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography. Once the DNA fragments have been generated, identification of the specific DNA fragment containing all or a portion of the GENE SET gene may be accomplished in a number of ways. In a preferred embodiment of the present invention, a GENE SET gene is isolated by use of the polymerase chain reaction (PCR), which can be utilized to amplify the desired GENE SET sequence within a genomic or cDNA library, or directly from genomic DNA or cDNA which has not been incorporated into a library. Synthetic oligonucleotides may then be utilized as primers in PCR-mediated amplification of sequences from an RNA or DNA source, preferably from a cDNA library, of potential interest. In addition, several different degenerate primers may be synthesized for use in the PCR amplification reactions. The PCR amplification reaction may be performed, for example, by use of a Perkin-Elmer Cetus ® Thermal Cycler and Taq polymerase (Gene AmpJ). It is also possible to vary the stringency of hybridization conditions utilized during the priming of the PCR amplification reactions, to allow for greater or lesser degrees of nucleotide sequence similarity between the known GENE SET nucleotide sequence and the nucleic acid of an GENE SET homolog being isolated. For cross-species hybridization, low stringency conditions are preferred. For same-species hybridization, moderately stringent conditions are preferred. Following successful amplification of a fragment or segment of a GENE SET homolog, that segment may be molecularly-cloned, sequenced and utilized as a probe to isolate a complete cDNA or genomic clone. This, in turn, will permit the subsequent determination and isolation of the gene's complete nucleotide sequence. Alternately, PCR amplification may also be used to detect and quantitate GENE SET mRNA levels. Additionally, a portion of a GENE SET gene or its associated mRNA (or a fragment thereof) may be purified, or an oligonucleotide synthesized, and the generated DNA fragments may be analyzed by nucleic acid hybridization to the labeled probe. See e.g., Benton & Davis, 1977. Science 196:180; Grunstein & Hogness, 1975. Proc. Natl. Acad. Sci. U.S.A. 72:3961. Those DNA fragments which possess substantial homology to the labeled oligonucleotide probe will hybridize. GENE SET nucleic acids may be also identified and isolated by expression cloning using, for example, anti-GENE SET antibodies for selection. Alternatives to obtaining the GENE SET DNA by cloning or amplification include, but are not limited to, chemically- synthesizing the gene sequence itself from the known GENE SET sequence or synthesizing a cDNA from the mRNA encoding the GENE SET protein of interest. It should be noted that the use of other methodologies is possible and within the scope of the present invention. Once a clone has been obtained, its identity may be ascertained by nucleic acid sequencing and computer database-mediated comparison to known GENE SET sequences. DNA sequence analysis may be performed by any techniques known within the art including, but not limited to: chemical-based sequencing (see Maxam & Gilbert, 1980. Meth. Enzymol. 65:499- 560); enzymatic dideoxynucleotide chain termination sequencing (see Sanger, et al., 1911. Proc. Natl. Acad. Sci. U.S.A. 74:5463); T7 DNA polymerase sequencing (see Tabor & Richardson, U.S. Patent No. 4,795,699); automated DNA sequenator (e.g., Applied Biosystems, Foster City, CA) or the sequencing methodology described in PCT Publication WO 97/15690. Nucleic acids which are hybridizable to a GENE SET nucleic acid (e.g., possessing a nucleotide sequence homologous or complementary to a nucleic acid encoding SEQ ID NOs:l, 6, 10-11, 14-15, 18-19, 26-27, 32-33, or 37), or a derivative or analog thereof, may be isolated by nucleic acid hybridization under conditions of low, moderate or high stringency. By way of example and not limitation, procedures using such conditions of low stringency are as follows (see also e.g., Shilo & Weinberg, 1981. Proc. Natl. Acad. Sci. USA 78:6789-6792): filters containing immobilized DNA were pre-hybridized for 6 hours at 40°C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 μ/ml denatured salmon sperm DNA. Hybridizations were performed in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 μg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate and 5-20 x 10 6 cpm 32 P-labeled probe was utilized. The filters were incubated in hybridization mixture for 18-20 hours at 40°C, and then washed for 1.5 hour at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA and 0.1% SDS. The wash solution was then replaced with fresh solution and the filters were re-incubated for an additional 1.5 hour at 60°C. The filters were blotted dry and autoradiographed. If necessary, filters were washed for a third time at 65-68°C and re-exposed to X-ray film. Various other conditions of low stringency hybridization which are well-known within the art may be utilized for low stringency hybridization protocols (e.g. , as employed for cross-species hybridizations). By way of example, but not of limitation, procedures utilizing conditions of moderate stringency hybridization are as follows: filters containing immobilized DNA were pre-hybridized for 6 hours at 55°C in a solution containing 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 μg/ml denatured salmon sperm DNA. Hybridizations were performed in the same solution and 5-20 x 10 6 cpm 32 P-labeled probe was utilized. The filters were incubated in hybridization mixture for 18-20 hours at 55°C and then washed twice for 30 minutes at 60°C in a solution containing IX SSC and 0.1% SDS. Filters were then blotted dry and autoradiographed. Other conditions of moderate stringency hybridizations which may be utilized are well-known within the art. Again, by way of example and not of limitation, procedures utilizing conditions of high stringency hybridization were as follows: pre-hybridization of filters containing immobilized DNA was carried out for 8 hours to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 μg/ml denatured salmon sperm DNA. Filters were hybridized for 48 hours at 65°C in pre-hybridization mixture containing 100 μg/ml denatured salmon sperm DNA and 5-20 x 10 6 cpm of 2 P-labeled probe. Washing of filters was done at 37°C for 1 hour in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll and 0.01% BSA. This was followed by a wash in 0.1X SSC at 50°C for 45 minuets prior to autoradiography. Other conditions of high stringency hybridization which may be used are well-known within the art. Nucleic acids encoding derivatives and analogs of GENE SET proteins, GENE SET anti- sense nucleic acids and primers which can be utilized to detect mutant GENE SET alleles and GENE SET gene expression are disclosed by the present invention. As used herein, a "nucleic acid encoding a fragment or portion of an GENE SET protein" refers to a nucleic acid encoding only the recited fragment or portion of the GENE SET protein, and not the other contiguous portions of the GENE SET protein as a continuous sequence. GENE SET proteins (and derivatives, analogs and fragments thereof) of GENE SET proteins may be obtained by any method known within the art including, but not limited to, recombinant expression methods, purification from natural sources, chemical synthesis and the like. For example, GENE SET proteins may be obtained by recombinant protein expression techniques, wherein the GENE SET gene or portion thereof is inserted into an appropriate cloning vector for expression within a particular host cell. A large number of vector-host systems known within the art may be used. Possible vectors include, but are not limited to, bacteriophage (e.g., lambda derivatives); plasmids (e.g., pBR322, pUC plasmid derivatives or the pBlueScript vector (Stratagene)) or other vector which are well-known within the art. The insertion of the DNA fragment of interest into a cloning vector may, for example, be accomplished by ligating the fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (e.g., linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative methodology, the digested vector and GENE SET gene may be modified by homopolymeric tailing. The recombinant molecule may subsequently introduced into the host cell via transformation, transfection, infection, electroporation, and the like, to facilitate the generation of a plurality of copies of the GENE SET gene sequence of interest. In an alternative methodology, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot-gun" approach. Enrichment for the desired gene by, for example, size fractionation, may be performed prior to its insertion into the cloning vector. In specific embodiments of the present invention, transformation of host cells with recombinant DNA molecules which incorporate the isolated GENE SET gene, cDNA or synthesized DNA sequence, facilitates the generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA. The nucleotide sequence encoding a GENE SET protein (or a functionally-active analog, fragment or other derivative thereof), may be inserted into an appropriate expression vector (i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence). Alternately, the necessary transcriptional and translational signals may also be supplied by the native GENE SET gene and/or its flanking regions. A variety of host- vector systems may be utilized to express the protein-coding sequence including, but are not limited to, mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be employed in the practice of the present invention. Any of the methodologies previously-described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombinants (i.e., genetic recombination). Expression of nucleic acid sequence encoding a GENE SET protein or peptide fragment, may be regulated by a second nucleic acid sequence so that the GENE SET protein or peptide is expressed within a host cell which has been transformed with the recombinant DNA molecule. For example, expression of a GENE SET protein may be controlled by any promoter/enhancer element known within the art including, but not limited to: ( ) the SV40 early promoter region (see e.g., Bernoist & Chambon, 1981. Nature 290:304-310); (ii) the promoter contained in the 3'-terminus long terminal repeat (LTR) of Rous sarcoma virus (see e.g., Yamamoto, et al., 1980. Cell 22:787-797); (iii) the Herpesvirus thymidine kinase promoter (see e.g., Wagner, et al., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445); (iv) the regulatory sequences of the metallothionein gene (see e.g., Brinster, et al., 1982. Nature 296:39- 42); (v) prokaryotic expression vectors such as the β-lactamase promoter (see e.g., Villa- Kamaroff, et al., 1978. Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731) or the tac promoter (see e.g., DeBoer, et al., 1983. Proc. Natl. Acad. Sci. U.S.A. 80:21-25). Additionally, the following animal transcriptional control regions, exhibiting tissue specificity, have been utilized in transgenic animals including: ( ) the elastase I gene control region which is active in pancreatic acinar cells (see e.g., Swift, et al., 1984. Cell 38:639-646); (ii) the insulin gene-control region which is active in pancreatic β-cells (see e.g., Hanahan, 1985. Nature 315:115-122); (iii) the immunoglobulin gene control region which is active in lymphoid cells (see e.g., Grosschedl, et al., 1984. Cell 38:647-658; (/ v ) the α-1-antitrypsin gene control region which is active in the liver (see e.g., Kelsey, et al., 1987. Genes and Devel. 1:161-171) and the β-globin gene control region which is active in myeloid cells (see e.g., Mogram, et al., 1985. Nature 315:338-340. In a specific embodiment of the present invention, a vector may be used which comprises a promoter operably-linked to a GENE SET-encoding nucleic acid, one or more origins of replication and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene). In another specific embodiment, an expression construct is produced by sub-cloning a GENE SET coding sequence into the EcøRI restriction site of each of the three pGΕX vectors (i.e., Glutathione S-Transferase expression vectors; Smith & Johnson, 1988. Gene 7:31-40), thus allowing the expression of the GΕNΕ SET protein-product in the correct reading frame. Expression vectors containing GENE SET gene inserts may be identified by the use of three general approaches: (i) nucleic acid hybridization; (ii) presence or absence of "marker" gene functions and (iii) expression of inserted nucleotide sequences. In the first approach, the presence of a GENE SET gene which has been inserted into an expression vector is detected by nucleic acid hybridization using oligonucleotide probes comprising sequences which are complementary to the aforementioned inserted GENE SET gene. In the second approach, the recombinant vector/host system is identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, and the like) which is caused by the insertion of the GENE SET gene of interest into the vector. Specifically, if the GENE SET gene is inserted into the marker gene sequence of the vector, the recombinant species possessing the GENE SET insert may be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors are identified by assaying the GENE SET protein product expressed by the recombinant. Such assays may be based, for example, upon the physical or functional properties of the GENE SET protein in various in vitro assay systems (e.g., binding of an anti-GENE SET protein antibody). Following the isolation and identification of the recombinant DNA molecule of interest, several methodologies well-known within the art may be employed for its propagation. Once a suitable host system and growth conditions have been established, the recombinant expression vectors may be propagated and prepared in quantity. As previously disclosed, expression vectors which may be utilized include, but are not limited to the following vectors or their derivatives: human or animal viruses (e.g., vaccinia virus or adenovirus); insect viruses (e.g., baculovirus); yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors; and the like. Similarly, a host cell strain may be chosen which modulates the expression of the inserted sequences or, alternately, modifies and processes the gene product in the specific fashion desired. Expression from certain promoters may be elevated by the presence of inducers; hence expression of the recombinant GENE SET protein may be controlled. Moreover, different host cells possess characteristic and/or specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins), thus appropriate cell lines or host systems may be chosen to ensure the desired modification and processing of the recombinant protein is accomplished. For example, expression of the recombinant protein in a bacterial system can be used to produce an non-glycosylated core protein product; whereas expression in yeast will produce a glycosylated protein product. Similarly, expression in mammalian cells may be utilized to ensure "wild-type" glycosylation of a heterologous protein. In other specific embodiments of the present invention, the GENE SET protein (or fragment, analog, or derivative) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence of a different protein). These chimeric products may be produced by the ligation of the appropriate nucleic acid sequences encoding the desired amino acid sequences to one another, in the proper reading frame, by methods known within the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques (e.g., by use of a peptide synthesizer). It should be noted that the cloning and subsequent expression of both cDNA and genomic DNA sequences are within the scope of the present invention. The recombinant GENE SET proteins of the present invention may also be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and partition column chromatography); centrifugation; differential solubility or by any other standard technique for the purification of proteins. In an alternate embodiment, native GENE SET proteins may be purified from natural sources utilizing standard methods such as those described above (e.g., immunoaffmity purification). In another embodiment, the GENE SET proteins may be synthesized by standard chemical methods known within the art (see e.g. , Hunkapiller, et al., 1984. Nature 310:105-111). The functional properties of the GENE SET proteins may be evaluated using any suitable assay. (3) Methods of Treatment The present invention discloses methodologies of treating and preventing ischemic and metabolic diseases and disorders by administration of a therapeutic compound (hereinafter designated "Therapeutics"). In one embodiment, such "Therapeutics" include GENE SET mutant proteins (and derivatives, fragments and analogs thereof), as well as nucleic acids which encode the mutant GENE SET proteins (and derivatives, fragments or analogs thereof). In another embodiment, the protein product, which are not produced as a direct result of the diminution of the activity of an enzyme indigenous to the GENE SET, may also be utilized as a Therapeutic of the present invention. As an example, but not a limitation, the mutation (i.e., amino acid substitution) in the kynurenine aminotransferase enzyme putatively blocks the enzyme's ability to produce kynurenic acid, a small, aqueous-soluble molecule which may function as an anti-hypertensive. In another embodiment, the Therapeutic is a mutant GENE SET protein possessing one or more substitutions of amino acid residues relative to the "wild-type" GENE SET protein The subject to which the Therapeutic is administered is preferably an animal including, but not limited to, animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal. In a preferred embodiment, the subject is a human. Generally, the administration of products of a species origin or species reactivity (in the case of antibodies) which is the same species as that of the subject is preferred. Thus, in a preferred embodiment, a human mutant GENE SET protein or nucleic acid (or derivative, fragment or analog thereof) is therapeutically or prophylactically administered to a human patient. Accordingly, in a specific embodiment of the invention ^ GENE SET antagonists and inhibitors including, but not limited to, anti-GENE SET antibodies and GENE SET anti-sense nucleic acids and GENE SET derivatives (e.g., which function as competitive inhibitors of GENE SET) are administered to treat or prevent stroke or ischemic disease, hypertension, diabetes or obesity. (a) Gene Therapy In a specific embodiment of the present invention, nucleic acids comprising a sequence encoding a GENE SET mutant protein (or derivative thereof) or a GENE SET anti-sense nucleic acid, are administered by way of gene therapy. Gene therapy refers to therapy performed by the administration of a nucleic acid to a subject. In this embodiment of the invention, the nucleic acid produces its encoded protein or is an anti-sense nucleic acid which mediates a therapeutic effect. Any of the methods for gene therapy which are well-known within the art may be utilized in the practice of the present invention. See e.g., Ausubel, et al., 1993. Current Protocols in Molecular Biology (John Wiley & Sons, New York, NY); Kriegler, 1990. Gene Transfer and Expression: A Laboratory Manual (Stockton Press, New York, NY). In a preferred embodiment, the Therapeutic comprises an GENE SET nucleic acid that is part of an expression vector that expresses an GENE SET protein or fragment or chimeric protein, preferably a mutant GENE SET protein or fragment or chimeric protein, or an GENE SET anti-sense nucleic acid thereof in a suitable host. In a specific embodiment, the nucleic acid possesses a promoter which is operably-linked to the mutant GENE SET coding region or to a sequence encoding an GENE SET anti-sense nucleic acid, wherein the promoter is inducible or constitutive and, optionally, tissue-specific. In another specific embodiment, a nucleic acid is used in which the mutant GENE SET coding sequences and any other desired sequences are flanked by regions which promote homologous recombination at a desired site in the genome, thus providing for intra-chromosomal expression of the mutant GENE SET nucleic acid. See e.g., Koller & Smithies, 1989. Proc. Natl. Acad. Sci. USA 86:8932-8935. Delivery of the nucleic acid into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vector, or indirect, in which case, cells are first transformed with the nucleic acid in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy. In a specific embodiment, the nucleic acid is directly administered in vivo, where it is expressed to produce the encoded product. This may be accomplished by any of numerous methods known in the art including, but not limited to, constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular by: (/ ' ) infection using a defective or attenuated retroviral or other viral vector (see e.g., U.S. Patent No. 4,980,286); (ii) direct injection of naked DNA; (iii) use of microparticle bombardment; (iv) coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules; (v) by administering it in linkage to a peptide which is known to enter the nucleus; (vi) administering it in linkage to a ligand subject to receptor- mediated endocytosis which can be used to target cell types specifically-expressing the receptors and the like. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see e.g., PCT Publications WO 92/06180 and WO 93/20221. Alternatively, the nucleic acid may be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination. See e.g., Zijlstra, et al, 1989. Nature 342:435-438. In a specific embodiment, a viral vector that contains the mutant GENE SET nucleic acid or codes for GENE SET anti-sense nucleic acid is used. For example, a retroviral vector can be used. See e.g., Miller, et al, 1993. Meth. Enzymol. 217:581-599. These retroviral vectors have been modified to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA. The GENE SET nucleic acid to be used in gene therapy is cloned into the vector, which facilitates delivery of the gene into a patient. See e.g., Clowes, et al, 1994. J. Clin. Invest. 93:644-651 ; Kiem, et al, 1994. Blood 83: 1467- 1473. Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. See e.g., Rosenfeld, et al, 1991 Science 252:431-434; Mastrangeli, et al, 1993. J. Clin. Invest. 9 _:225-234. In addition, adeno-associated virus (AAV) has also been proposed for use in gene therapy. See e.g., Walsh, et al., 1993. Proc. Soc. Exp. Biol. Med. 204:289-300 (1993). Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient. In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, and the like. Numerous techniques are well-known within the art for the introduction of foreign genes into cells (see e.g., Loeffler & Behr, 1993. Meth. Enzymol. 217:599-618) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny. The resulting recombinant cells can be delivered to a patient by various methods known in the art. In a preferred embodiment, epithelial cells are injected (e.g., subcutaneously). In another embodiment, recombinant skin cells may be applied as a skin graft onto the patient. Recombinant blood cells (e.g. , hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art. Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells (e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, and the like). In a preferred embodiment of the present invention, the cell used for gene therapy is autologous to the patient. In an embodiment in which recombinant cells are used in gene therapy, a mutant GENE SET nucleic acid or nucleic acid encoding a GENE SET anti-sense nucleic acid is introduced into the cells such that it is expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro may potentially be used in accordance with this embodiment of the present invention. Such stem cells include but are not limited to hematopoietic stem cells (HSC), stem cells of epithelial tissues such as the skin and the lining of the gut, embryonic heart muscle cells, liver stem cells (see e.g., PCT Publication WO 94/08598) and neural stem cells (see e.g., Stemple & Anderson, 1992. Ce// 71:973-985). Epithelial stem cells (ESCs) or keratinocytes can be obtained from tissues such as the skin and the lining of the gut by known procedures. See e.g., Rheinwald, 1980. Meth. Cell Bio. 21A:229. In stratified epithelial tissue such as the skin, renewal occurs by mitosis of stem cells within the germinal layer, the layer closest to the basal lamina. ESCs or keratinocytes obtained from the skin or lining of the gut of a patient or donor can be grown in tissue culture. See e.g., Pittelkow & Scott, 1986. Mayo Clinic Proc. 6J_:771. If the ESCs are provided by a donor, a method for suppression of host versus graft reactivity (e.g., irradiation, drug or antibody administration to promote moderate immunosuppression) may also be utilized. With respect to hematopoietic stem cells (HSC), any technique that provides for the isolation, propagation, and maintenance in vitro of HSC can be used in this embodiment of the invention. Techniques by which this may be accomplished include: (i) the isolation and establishment of HSC cultures from bone marrow cells isolated from the future host, or a donor or (//) the use of previously established long-term HSC cultures, which may be allogeneic or xenogeneic. Non-autologous HSC are used preferably in conjunction with a method of suppressing transplantation immune reactions of the future host/patient. In a particular embodiment of the present invention, human bone marrow cells can be obtained from the posterior iliac crest by needle aspiration. See e.g., Kodo, et al, 1984. J. Clin. Invest. 73:1377- 1384. In a preferred embodiment of the present invention, the HSCs can be made highly enriched or in substantially-pure form. This enrichment can be accomplished before, during or after long-term culturing, and can be done by any techniques known in the art. Long-term cultures of bone marrow cells can be established and maintained by using, for example, modified Dexter cell culture techniques (see Dexter, et al, 1977. J. Cell Physiol. 91:335) or Witlock-Witte culture techniques (see Witlock & Witte, 1982. Proc. Natl. Acad. Sci. USA 79:3608-3612). In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably-linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. (b) Anti-GENE SET Antibodies In one embodiment of the present invention, as previously discussed hereinabove, antibodies which bind GENE SET proteins or nucleic acids (or derivative, fragments or analogs thereof) are used to treat or prevent hypertension, diabetes, obesity or ischemic stroke. Anti- GENE SET antibodies may also be used in the diagnostic, prognostic and screening methods of the present invention. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. In a specific embodiment, antibodies to a human GENE SET protein are produced. In another specific embodiment, antibodies which reduce or inhibit GENE SET activity in vitro and/or in vivo, are provided. Various procedures known in the art may be used for the production of polyclonal antibodies to an GENE SET protein or derivative or analog. In a particular embodiment, rabbit polyclonal antibodies to an epitope of a GENE SET protein (e.g., the protein of amino acid sequences SEQ ID NOS: 1, 6, 10-11, 14-15, 18-19, 26-27, 32-33, or 37, or a subsequence thereof, or nucleic acids encoding sequences or subsequences thereof) may be obtained. For the production of antibody, various host animals can be immunized by injection with the native GENE SET protein, a synthetic version, or a derivative or fragment thereof including, but not limited to, rabbits, mice, rats, and the like. Various adjuvants may be used to increase the immunological response, depending on the host species (e.g., Freund's adjuvant). For preparation of monoclonal antibodies directed toward an GENE SET protein sequence (or derivative or analog thereof) any technique which provides for the production of antibody molecules by continuous in vitro cell lines may be used including, but not limited to: the hybridoma technique (see Kohler & Milstein, 1975. Nature 256:495-497); the trioma technique; the human B-cell hybridoma technique (see Kozbor, 1983. et al, Immunology Today 4:72) and the EBV-hybridoma technique to produce human monoclonal antibodies (see Cole, et al, Monoclonal Antibodies and Cancer Therapy (Alan R. Liss, Inc., New York, NY). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (see e.g., PCT Publication US90/02545). Human antibodies are within the scope of the present invention and may be obtained by using human hybridomas (see e.g., Cote, et al, 1983. Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B-cells with Epstein-Barr virus (EBV) in vitro (see e.g., Cole, et al, 1985. Monoclonal Antibodies and Cancer Therapy (Alan R. Liss, New York, NY). Additionally within the scope of the present invention are the production of "chimeric antibodies" (see e.g., Morrison, et al, 1984. Proc. Natl. Acad. Sci. U.S.A. 81:6851-6855) which may be produced by splicing the genes from a mouse antibody molecule specific for GENE SET together with genes from a human antibody molecule of appropriate biological activity. In one embodiment of the present invention, single chain antibodies (see U.S. Patent No. 4,946,778) may be adapted to produce GENE SET-specific single chain antibodies. An additional embodiment of the invention discloses the utilization of Fab expression libraries (see e.g., Huse, et al, 1989. Science 246:1275-1281) so as to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for GENE SET proteins (or derivatives or analogs thereof). Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab') 2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab'), fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments. In the production of antibodies, screening for the desired antibody may be accomplished by techniques known in the art (e.g., enzyme-linked immunosorbent assay(ELISA)). In a specific embodiment, the selection of antibodies which recognize a specific portion of an GENE SET protein may be accomplished by an assay which utilize hybridomas specific for a product which binds to a GENE SET fragment containing such portion. For selection of an antibody which possesses the ability to reduce or inhibit GENE SET activity, one may screen the antibody in any of the assays for GENE SET activity described infra. (c) Anti-Sense GENE SET Nucleic Acids In a specific embodiment of the present invention, the function of GENE SET protein(s) is reduced or inhibited by GENE SET anti-sense nucleic acids, utilized to treat or prevent stroke, hypertension, diabetes or obesity. The present invention provides the therapeutic or prophylactic use of nucleic acids of at least six nucleotides which are anti-sense to a gene or cDNA encoding GENE SET or a portion thereof. An GENE SET "anti-sense" nucleic acid, as utilized herein, refers to a nucleic acid species which is capable of hybridizing to a portion of an GENE SET RNA (preferably mRNA) by virtue of sequence complementarily. The anti-sense nucleic acid may be complementary to a coding and/or noncoding region of an GENE SET mRNA. Such anti-sense nucleic acids have utility as Therapeutics that reduce or inhibit GENE SET function, and can be used in the treatment or prevention of disorders as described, supra. The GENE SET anti-sense nucleic acids are of at least six nucleotides and are preferably oligonucleotides (ranging from 6-150 nucleotides or, more preferably, 6-50 nucleotides). In specific aspects, the oligonucleotide is at least 10 nucleotides, at least 15 nucleotides, at least 100 nucleotides, or at least 125 nucleotides. The oligonucleotides may be DNA, RNA or chimeric mixtures (or derivatives or modified versions thereof) and may be single-stranded or double- stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, or agents facilitating transport across the cell membrane (see e.g., Letsinger, et al, 1989. Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556) or blood-brain barrier (see e.g., PCT Publication No. WO 89/10134); hybridization-triggered cleavage agents (see e.g., Krol, et al, 1988. BioTechniques 6:958-976) or intercalating agents (see e.g., Zon, 1988. Pharm. Res. 5:539-549). The GENE SET anti-sense nucleic acid of the present invention is preferably an oligonucleotide and more preferably, a single-stranded DNA. In a preferred embodiment, the oligonucleotide comprises a sequence anti-sense to a portion of human GENE SET. The oligonucleotide may be modified at any position on its structure with substituents generally known within the art. Oligonucleotides of the invention may be synthesized by standard methods known within the art, for example, by use of an automated DNA synthesizer (e.g., Biosearch, Applied Biosystems, etc). As an example, but of limitation, phosphorothioate oligonucleotides may be synthesized by the method of Stein, et al. (1988. Nucl Acids Res. 16:3209); methylphosphonate oligonucleotides may be prepared by use of controlled pore glass polymer supports (see e.g., Sarin, et al, 1988. Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451) and similar synthesis methodologies.. In a specific embodiment of the present invention, the GENE SET anti-sense oligonucleotide comprises catalytic RNA or a ribozyme (see e.g. , PCT International Publication WO 90/11364; Sarver, et al, 1990. Science 247:1222-1225). In another specific embodiment, the oligonucleotide is a 2N-0-methylribonucleotide (see e.g., Inoue, et al, 1987. Nuc. Acids Res. 15:6131-6148) or a chimeric RNA-DNA analogue (see e.g., Inoue, et al, 1987. FEBS Lett. 215:327-330). In another embodiment, the GENE SET anti-sense nucleic acid of the present invention is produced intracellularly by in vivo transcription from an exogenous sequence. For example, a vector may be introduced in vivo such that the vector (or a portion thereof) is transcribed, producing an anti-sense nucleic acid (RNA) of the present invention. Such a vector would contain a sequence encoding the GENE SET anti-sense nucleic acid, and can remain episomal or become chromosomally-integrated, so long as it can be transcribed to produce the desired anti- sense RNA. The aforementioned vectors may be comprised of plasmid, viral, or others known in the art which are utilized for replication and expression in mammalian cells and may be constructed by recombinant DNA technology methodologies standard within the art. Expression of the sequence encoding the GENE SET anti-sense RNA may be by any promoter known in the art to act in mammalian, preferably human, cells. Such promoters can be inducible or constitutive and include, but are not limited to: (i) the SV40 early promoter region (see e.g., Bernoist & Chambon, 1981. Nature 290:304-310); (ii) the promoter contained in the 3 '-terminus long terminal repeat (LTR) of Rous sarcoma virus (see e.g., Yamamoto, et al, 1980. Cell 22:181-191); (iii) the Herpesvirus thymidine kinase promoter (see e.g., Wagner, et al, 1981. Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445); (iv) the regulatory sequences of the metallothionein gene (see e.g., Brinster, et al, 1982. Nature 296:39-42), and the like. The anti-sense nucleic acids of the present invention comprise a sequence complementary to at least a portion of an RNA transcript of an GENE SET gene, preferably a human GENE SET gene. However, absolute complementarily, although preferred, is not a requirement. A sequence "complementary to at least a portion of an RNA," as utilized herein refers to a sequence possessing sufficient complementarily to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded GENE SET anti-sense nucleic acids. Similarly, a single strand of the duplex DNA or triplex formation may be assayed in a similar manner. The ability to hybridize will dependent upon both the degree of complementarily and the length of the anti- sense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with a an GENE SET RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art may ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex. The invention further provides pharmaceutical compositions (i.e., "Therapeutics') comprising an effective amount of the GENE SET anti-sense nucleic acids of the present invention within a pharmaceutically acceptable carrier. In a specific embodiment, pharmaceutical compositions comprising GENE SET anti-sense nucleic acids may be administered via liposomes, microparticles, or microcapsules. It may be useful to use such compositions to achieve sustained release of the GENE SET anti-sense nucleic acids. The amount of GENE SET anti-sense nucleic acid which will be effective in the treatment or prevention of ischemic disease will depend on the nature of the disease, and can be determined by standard clinical techniques. Where possible, it is desirable to determine the anti- sense cytotoxicity in cells in vitro, and then in useful animal model systems prior to testing and use in humans. (4) Methods of Diagnosis, Prognosis and Screening The present invention also discloses methodologies which relate to the diagnosis, prognosis and screening of stroke, hypertension, diabetes and/or obesity. In one embodiment, anti-GENE SET-antibodies are used to detect and quantitate mutant GENE SET levels in one or more tissues (e.g., blood) of a subject by use of an immunoassay- based methodology. Specifically, such an immunoassay is performed by contacting a sample derived from a patient with an anti-GENE SET antibody under conditions such that immunospecific-binding can occur, and detecting or measuring the amount of any immunospecific-binding by the antibody. It should be noted, however, that the particular amino acid deletion, insertion or substitution within the amino acid sequence of the mutant GENE SET protein can change the epitope recognized by a specific anti-(wild-type) GENE SET antibody, such that antibody may bind the mutant GENE SET protein to a lesser extent, or not at all. Additionally, antibodies may be generated against the mutant GENE SET protein, or portion thereof, which bind specifically to the particular mutant GENE SET, but not the wild-type GENE SET (as determined by the in vitro immunoassay methodology described infra). These specific anti-mutant GENE SET antibodies may be used to detect the presence of GENE SET by measuring the immunospecific-binding by the anti-mutant GENE SET antibodies and, optionally, the lack of immunospecific-binding by the anti-(wild-type) GENE SET antibodies. Moreover, GENE SET proteins possessing deletion or insertion mutations may be detected by either an increase or decrease in protein size by methodologies which include, but are not limited to, for example, but not limited to, Western blot analysis using an anti-GENE SET antibody which recognizes both the mutant and wild-type GENE SET. Immunoassays which may be utilized in the practice of the present invention include, but are not limited to, competitive and non-competitive assay systems using techniques such as Western blots, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays(ELISA), "sandwich" immunoassays, immunoprecipitation assays, precipitation reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein-A immunoassays, and the like. In a specific embodiment of the present invention, methods of diagnosis, prognosis and screening are disclosed and utilize the detection of mutant GENE SET alleles in genomic DNA or mRNA (i.e., genetic screening). These aforementioned mutant GENE SET alleles may be detected by any method known in the art for detecting mutations in genomic DNA including, but not limited to: DNA hybridization methods (e.g. Southern Blotting), RFLP mapping, PCR-based amplification methodologies, and the like, may be used with nucleic acid probes which are complementary to both the mutation and the corresponding position within the wild-type GENE SET sequence. In a preferred embodiment, allele-specific PCR (ASP) may be used to detect mutant GENE SET alleles. In the ASP methodology, a target DNA is, preferentially, amplified only if it is completely complementary to the 3'-terminus of a specific PCR amplification primer. The 3'- terminus of the primer is designed so as to terminate at, or within one or two nucleotides of a known mutation site within the GENE SET gene (target DNA) to which it possesses a complementary sequence. Under the appropriate reaction conditions, the target DNA is not amplified if there is a single nucleotide mismatch (e.g., a nucleotide substitution caused by a mutation) or a small deletion or insertion, at the 3'-terminus of the primer. See e.g., Okayama, et al, 1989. J. Lab. Clin. Med. 1 14: 105-1 13; Sommer, et al, 1992. BioTechniques 12:82-87). Accordingly, ASP may be utilized to detect either the presence or absence of (at least) a single nucleotide mismatch between the primer sequence (which is complementary to the pre-selected GENE SET target sequence) and a nucleic acid within the sample. Amplification of the GENE SET sequence is indicative of a lack of even a single mismatched nucleotide. Additionally, where the mutant comprises a deletion or insertion mutation, mutant GENE SET alleles may be detected by screening for an increase or decrease in the length of the GENE SET nucleic acid sequence, or portion thereof. The increase or decrease in length may be detected by any method known within the art for measuring the length of nucleic acids, including, but not limited to, amplification of a specific fragment of the GENE SET sequence from the subject to be diagnosed or screened and from a standard or control sample and comparison of the length of the fragments by any size fractionation method (e.g., denaturing polyacrylamide gel electrophoresis. Additionally, kits for diagnostic or screening use are also disclosed herein which comprise, in one or more containers, an anti-GENE SET antibody or anti-GENE SET mutant antibody and, optionally, a labeled binding partner to the antibody. Alternatively, the anti-GENE SET antibody or anti-GENE SET mutant antibody may be detectably-labeled (e.g., with a chemiluminescent, enzymatic, fluorescent, or radioactive moiety). In another embodiment, a kit is provided which comprises, in one or more containers, a nucleic acid probe which is capable of specifically-hybridizing to GENE SET RNA or, preferably, to mutant GENE SET RNA. In a specific embodiment of the present invention, a kit is provided which comprises, in one or more containers, a pair of primers (e.g., each in the size range of 6-30 nucleotides) which are capable of priming amplification reactions, under appropriate reaction conditions, of at least a portion of a GENE SET nucleic acid. These amplification reactions include, but are not limited to, polymerase chain reaction (PCR); ligase chain reaction; Qβ replicase, cyclic probe reaction or other amplification methods known within the art. A kit may, optionally, further comprise, in a container, a predetermined concentration of a purified GENE SET protein or nucleic acid, for use as a standard or control. (5) Assays for Modulators of GENE SET Proteins and Nucleic Acids A variety of methodologies are available within the art for assaying the activity of GENE SET proteins (and derivatives, analogs, fragments and homologs of GENE SET proteins), as well as for the nucleic acids encoding the GENE SET proteins (and derivatives, analogs, fragments and homologs thereof). Methods are also available for the screening of putative GENE SET modulators (e.g., GENE SET agonists, antagonists and inhibitors). Such modulators of GENE SET activity include, but are not limited to, GENE SET anti-sense nucleic acids, anti-GENE SET antibodies, and competitive inhibitors of GENE SET proteins for binding to the GENE SET protein receptors. The activity of the GENE SET proteins (and derivatives, fragments, analogs and homologs of GENE SET proteins), the nucleic acids encoding these GENE SET proteins (and derivatives, fragments, analogs and homologs thereof) and putative modulators of GENE SET protein activity may also be ascertained in vivo. For example, infusion of GENE SET proteins in humans causes significant increases in cGMP levels in plasma and urine. See e.g., Vesely, et al, 1995. Am. J. Med. Sci. 310:143-149; Vesely, et al, 1996. Metabolism: Clin. & Exp. 45:315-319. Administration of GENE SET proteins to humans also elicits significant diuresis and reduction in blood pressure (see e.g., Vesely, et al, 1996. Life Sciences 59:243-254); similar effects have also been observed in rodents (see e.g., Garcia, et al, 1989. Hypertension l_3:567-574). In accord, the mutant GENE SET proteins and nucleic acids (and derivatives, analogs, fragments and homologs thereof) and putative GENE SET modulators may be assayed by the administration of a "test compound" to an animal, preferably a non-human test animal, followed by the measurement of the one or more of the physiological parameters described above (e.g., cGMP levels in urine and/or plasma, diuretic effect, decrease in blood pressure, and the like). Another embodiment of the present invention discloses a methodology for screening a GENE SET mutant for a change in activity comprising (i) administering the GENE SET mutant to a test animal prone to stroke, hypertension, diabetes or obesity and (ii) measuring of stroke latency within the test animal in which stroke latency is indicative of GENE SET activity. In a specific embodiment, a recombinant test animal, which expresses a GENE SET transgene or expresses a member of the GENE SET under the control of a promoter which is not the native GENE SET gene promoter at an increased level relative to a wild-type test animal, is used to screen the GENE SET for a change in GENE SET activity. In another embodiment of the present invention, a method for screening for a modulator of GENE SET activity, or of latency or predisposition to stroke, is provided which comprises measuring stroke latency within a stroke-prone animal that recombinantly expresses a putative modulator of GENE SET activity, in which a change in stroke latency relative to an analogous stroke-prone animal which does not recombinantly-express the putative modulator, indicates that the putative modulator possesses the ability to modulate GENE SET activity, or latency or predisposition to stroke. In yet another embodiment, a method is provided for screening an GENE SET mutant for an effect on latency or predisposition to stroke comprising measuring stroke latency within a stroke-prone animal which recombinantly-expresses a GENE SET mutant, in which a change in stroke latency relative to an analogous stroke-prone animal which does not recombinantly express the GENE SET mutant indicates that the GENE SET mutant has an effect on latency or predisposition to stroke, hypertension, diabetes or obesity. In a preferred embodiment, a GENE SET mutant is screened for an increase in stroke latency or a decrease in predisposition to stroke. (6) Pharmaceutical Compositions and Therapeutics The present invention discloses methods of treatment and prophylaxis by administering to a subject of an effective amount of a Therapeutic of the invention. In a preferred embodiment, the Therapeutic is substantially-purified. The subject is preferably an animal which, preferably, is a mammal and most preferably human. Formulations and methods of administration which may be employed when the Therapeutic comprises a nucleic acid are described in Sections 3(a) and 3( c), supra; whereas additional appropriate formulations and routes of administration may be selected from among those described infra. Numerous types of pharmaceutical composition delivery systems are well-known within the art and may be utilized to administer a Therapeutic of present the invention. These aforementioned delivery systems include, but are not limited to: (ϊ) encapsulation in liposomes, microparticles and microcapsules; (ii) recombinant cells capable of expressing the Therapeutic; (iii) receptor-mediated endocytosis (see e.g., Wu & Wu, 1987. J Biol. Chem. 262:4429-4432): (iv) construction of a Therapeutic nucleic acid as part of a retroviral or other vector, and the like. Methods of administration/introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The Therapeutic may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the Therapeutic of the present invention into the central nervous system by any suitable route (e.g., intraventricular and intrathecal injection). Intraventricular injection may be facilitated by the use of an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration may also be employed (e.g., by use of an inhaler or nebulizer) and formulation with an aerosolizing agent. In a specific embodiment of the present invention, it may be desirable to administer the Therapeutic of the present invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application (e.g., in conjunction with a wound dressing after surgery), by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In another specific embodiment of the present invention, the Therapeutic may be delivered in a vesicle, in particular a liposome. See e.g., Langer, 1990. Science 249: 1527-1533. In yet another specific embodiment, the Therapeutic may be delivered via a controlled release system including, but not limited to: a pump (see e.g., Sefton, 1987. CRC Crit. Ref Biomed. Eng. 14:201) and polymeric materials (see e.g., Smolen & Ball, 1983. Controlled Drug Bioavailability, Drug Product Design and Performance (Wiley, New York, NY). In addition, a controlled release system may be placed in proximity of the therapeutic target (e.g., the brain), thus requiring only a fraction of the total systemic dose. See e.g., Goodson, 1984. Medical Applications of Controlled Release, (Wiley, New York, NY). In a specific embodiment of the present invention where the Therapeutic is a nucleic acid encoding a protein-based Therapeutic, the nucleic acid may be administered in vivo to promote expression of its encoded protein, by constructing of the aforementioned protein as part of an appropriate nucleic acid expression vector, and administering the construct so that it becomes intracellular by methodologies which include, but are not limited to: (i) use of a retroviral vector (see e.g., U.S. Patent No. 4,980,286); (ii) use direct injection; (iii) use of microparticle bombardment (e.g., a gene gun; Biolistic, DuPont); (iv) coating_with lipids or cell-surface receptors or transfecting agents; (v) administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see e.g., Joliot, et al, 1991. Proc. Natl. Acad. Sci. USA 88:1864- 1868) and the like. In an alternate embodiment of the present invention, a nucleic acid-based Therapeutic may be introduced intracellularly and incorporated by homologous recombination within host cell DNA for expression. The present invention also discloses pharmaceutical compositions. Such compositions comprise a therapeutically-effective amount of a Therapeutic within a pharmaceutically- acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable," as utilized herein, is defined as the composition being approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals and, more particularly, in humans. The term "carrier," as utilized herein, refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers include, but are not limited to: sterile liquids (e.g., water, physiological saline and the like) and oils (e.g., oils of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like). Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Additionally, saline solutions and aqueous dextrose and glycerol solutions may also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in Martin, 1965. Remington's Pharmaceutical Sciences. Such compositions will contain a therapeutically-effective amount of the Therapeutic, preferably in purified form and, most preferably, in a substantially-purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should be suited to the mode of administration. In a preferred embodiment of the present invention, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration. The Therapeutics of the present invention may be formulated with pharmaceutically- acceptable salts including those derived from hydrochloric, phosphoric, acetic, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc. The amount of the Therapeutic of the present invention which will be effective in the treatment of a particular disorder or condition will be dependent upon the exact nature of the disorder or condition, and can be quantitatively-determined by standard clinical techniques. In addition, in vitro assays may (optionally) be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for intravenous administration are generally about 20-500 μg of active compound per kilogram (kg) body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient. The present invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s), a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. (7) Animal Models The present invention discloses animal models. In one embodiment, animal models for stroke, hypertension, diabetes or obesity are provided. Transgenic animals may be bred or produced through molecular-biological means, which over-express or under-express one or more of the GENE SET genes (e.g., by introducing a member or members of the GENE SET gene under the control of a heterologous promoter or a promoter which facilitates the expression of GENE SET proteins and/or nucleic acids in tissues which do not normally express GENE SET components. Additionally, "knockout" mice may be initially produced by promoting homologous recombination between a GENE SET gene in its chromosome and an exogenous GENE SET gene that has been rendered biologically inactive, preferably by insertion of a heterologous sequence (e.g., an antibiotic resistance gene) or by non-homologous recombination. In a preferred embodiment of the present invention, introduction of heterologous DNA is carried out by transforming embryo-derived stem (ES) cells with a vector containing the insertionally-inactivated GENE SET gene or a GENE SET gene which is under the control of a heterologous promoter, followed by injecting the ES cells into a blastocyst and implanting the blastocyst into a "foster mother" animal. Accordingly, the resulting mice are chimeric animals ("knockout animal" or "transgenic animal") in which an GENE SET gene has been inactivated or overexpressed or misexpressed (see e.g., Capecchi, 1989. Science 244:1288-1292). The chimeric animal can then be bred to produce additional knockout or transgenic animals. Such chimeric/transgenic animals include, but are not limited to, mice, hamsters, sheep, pigs, cattle, etc., and are, preferably, non-human mammals. Transgenic and knockout animals can also be made in D. melanogaster, C. elegans, and the like, by methods which are commonly-known within the art. Another embodiment of the present invention provides a recombinant non-human animal containing a mutant GENE SET gene, under the control of a promoter which is not the native GENE SET gene promoter, in which the mutant GENE SET gene encodes a mutant GENE SET which increases latency to stroke. Yet another embodiment discloses a recombinant non-human animal that is the product of a process comprising introducing a nucleic acid into the non-human animal, or an ancestor thereof, said nucleic acid comprising a mutant GENE SET gene sequence. SPECIFIC EXAMPLES Heart, brain, fat, liver and kidney tissues from spontaneously hypertensive rats (SHR), stroke-prone SHR (SHR-SP) and control Wistar Kyoto rats (WKY) were analyzed by the GeneCalling ® methodology (see U. S. Patent No. 5,871,697) to facilitate the identification and characterization of genes which are differentially-expressed in the SHR and SHR-SP rats, as compared to the control WKY animals. Materials and Methods Animals. Male SHR, SHRSP and WKY rats (Charles River Labs., Inc.) aged 6-7 weeks were co-acclimated for at least 1 week prior to euthanasia, fed pelleted rat chow and water ad libitum, and housed in a light- and temperature-controlled room. Isolation of Total Cellular RNA and Poly(A) + mRNA SHR, SHR-SP and WKY rats were maintained on normal rat chow (Purina) and water ad libitum. Thirteen week old rats were sacrificed and the hearts, liver, fat, kidney and brain tissues were removed and quick-frozen in liquid nitrogen immediately following dissection. The whole organs were stored at -70 ° C for subsequent processing. Total cellular RNA was extracted from 5 mg of heart, liver, fat, kidney, or brain tissue by initially grinding the tissue into a fine powder in liquid nitrogen. The powdered tissue was then transferred to a tube containing 500 μl Trizol Reagent ® (Life Technologies; Gaithersburg, MD) and was dispersed in the Trizol Reagent ® using a Polytron homogenizer (Brinkman Instruments; Westbury, NY). See e.g., Chomszynski, et al. 1987. Anal. Biochem. 162 156-159; Chomszynski, et al, 1993. BioTechniques L5:532-533, 536-537. The total cellular RNA fraction was then extracted with 50 μl l-bromo-3-chloropropane (Molecular Research Center, Inc.; Cincinnati, OH) to facilitate phase separation. The extraction mixture was centrifuged for 15 minutes at 4°C at 12,000 x G, and the aqueous phase was removed and transferred to a fresh tube. Contaminating DNA was optionally removed at this stage by treatment with DNase I (Promega, Madison, WI) in the presence of 0.01M DTT (BRL) and lu/μl RNasin (Promega). The RNA was then precipitated with 0.5 volume of isopropanol per original volume of Trizol Reagent ® used, and the sample was re-centrifuged at room temperature for 10 minutes at 12,000 x G. The supernatant was then discarded, the pellet washed with 70% ethanol and re-centrifuged at room temperature for 5 minutes at 12,000 x G. Finally the 70% ethanol was removed and the centrifuge tube was inverted and let stand to dry in this position. The resulting RNA pellet was re-suspended in 100 μl water (i.e., 1 μl/mg of original tissue weight) and heated to 55°C until completely dissolved. The final concentration of total cellular RNA was quantitated by fluorometry with OliGreen ® (Molecular Probes; Eugene, OR). In addition, the quality of the total cellular RNA was determined by both spectrophotometry and formaldehyde agarose gel electrophoresis. Alternatively, the RNA was obtained by phenol/chloroform extraction, and the RNA quality was again evaluated by spectrophotometry and formaldehyde agarose gel electrophoresis. Poly(A) + RNA was prepared from 100 μg of total cellular RNA by use of affinity chromatography with oligo(dT) magnetic beads (PerSeptive; Cambridge, MA) or with the Dynabeads mRNA Direct Kit ® (Dynal; Oslo, Norway) as directed by the manufacturer. The resulting product was harvested in a small volume of sterile water, and the final yield quantified by OD 260 measurement and fluorometry with OliGreen ® (Molecular Probes; Eugene, OR). The Poly(A) + RNA was stored at -20 ° C for subsequent utilization in cDNA synthesis and GeneCalling ® protocols. cDNA Synthesis Prior to cDNA synthesis, each of the Poly(A) + RNA samples from the aforementioned tissues were treated with DNase to remove endogenous, contaminating DNA if the sample had not been treated at the optional stage above. 28 μl of 5X reverse transcriptase buffer (Life Technologies; Gaithersburg, MD), 10 μl 0.1 M DTT, 5 units RNAguard ® (Pharmacia Biotech, Uppsala, Sweden) per 100 mg tissue and 1 unit RNase-free DNase I (Pharmacia Biotech) per 100 mg tissue, were added to the re-suspended RNA samples. The reaction mixtures were then incubated at 37 ° C for 20 minutes. The total RNA concentration was quantified by measuring OD 260 of a 100-fold dilution and the samples were stored at -20°C. cDNA was synthesized from the Poly(A) " RNA as follows: 1.0 μg of the Poly(A) + RNA isolated from each of the aforementioned tissues was mixed with 50 ng random hexamer primers (50 ng/μl) in 10 μl of water. The mixtures were heated to 70°C for 10 minutes, quick-chilled in an ice- water slurry, and kept on ice for 1-2 min. The condensates were then collected by centrifugation in a microfuge for approximately 10 seconds. The first-strand synthesis was performed by adding to the reaction mixtures: 4 μl 5x first- strand buffer (from a BRL cDNA Synthesis Kit; Grand Island, NY), 2 μl 100 mM DTT, 1 μl 10 mM dNTP mix, and 2 μl water to each of the primer-annealed Poly(A) + RNA. Alternatively, 200 pmols of oligo(dT)25V (V = A, C or G) [SEQ ID NO:43] was utilized as a primer in the first- strand synthesis reactions. The reaction mixtures were then incubated at 37 ° C for 2 min, followed by the addition of 1 μl containing 400 u of Superscript II ® reverse transcriptase (BRL) and the reactions were incubated at 37 ° C for 1 hour. Second-strand cDNA synthesis was then performed. The samples were placed on ice and to each of the first-strand reaction mixture was added: 30 μl of 5X second-strand buffer, 90 μl of cold water, 3 μl of 10 mM dNTP, 1 μL (10 units) of E. coli DNA ligase (BRL), 4 μl (40 units) of E. coli DNA polymerase I (BRL), and 1 μl (3.5 units) of E. coli RNaseH (BRL) and the reaction mixtures were incubated for 2 hours at 16°C. The resulting double-stranded cDNA was then incubated with 2 μl of T4 DNA polymerase (5 units) at 16°C for 5 min. The resulting cDNA was then dephosphorylated with Arctic Shrimp Alkaline Phosphatase ("SAP"; USB; Cleveland OH) by adding to each reaction mixture: 20 μl 10X SAP buffer, 25 μl of water, and 5 μl (5 units) of SAP. The reactions were incubated at 37°C for 30 min. The cDNA was extracted with phenol/chloroform (50:50 v/v), chloroform/isoamyl alcohol (99:1 v/v) and precipitated from the aqueous phase by the addition of NaOAc pH 5.0 to 0.3 M, 20 μg glycogen, and 2.5 volumes of ethanol followed by incubation at -20°C for 10 min. The cDNA was collected by centrifugation at 14,000 x g for 10 min. The supernatant was then aspirated and the resulting cDNA pellet was washed with 75% ethanol, resuspended in TE buffer (pH 7.0) and the yield of cDNA was estimated using fluorometry with Picogreen ® (Molecular Probes; Eugene, OR). GeneCalling ® Methodology The GeneCalling ® methodology includes a 3-step process which involves cDNA - fragmentation, tagging and amplification (see U. S. Patent No. 5,871,697) and in Shimkets et al. (1999. Nat Biotech 17, 798-803). Fragmentation was achieved by conducting separate restriction enzyme digestions for each of up to 96 pairs of restriction endonucleases in a 50 μl reaction mix containing 5 units of each of the two restriction enzymes constituting a pair, 1 ng of double- stranded cDNA and 5 μl of the appropriate 10X restriction endonuclease buffer. Analysis of all mRNAs was achieved by performing between 80 and 96 separate sets of cDNA fragmentation reactions, each with a different pair of restriction enzymes. Tagging was achieved by ligation of amplification cassettes with ends compatible to the 5'- and 3 '-termini of the cDNA fragments. A fluorescamine (FAM) label was incorporated onto the 5'-terminus of one of the PCR primers, and a biotin label into the second primer. Incubation of the ligation reaction was performed at 16°C for 1 hour in 10 mM ATP, 2.5% PEG, 10 units T4 DNA ligase and IX ligase buffer. PCR amplification was performed by the addition of the following reagents to each of the reaction tubes: 2 μl 10 mM dNTP, 5μl 10X TB buffer (500 mM Tris, 160 mM (NH 4 ) 2 SO 4 , 20 mM MgCl 2 , pH 9.15), 0.25 μl KlenTaq ® (Clontech Advantage) :PFU ® (Stratagene, La Jolla CA) (16:1) and 32.75 μl H 2 O and two universal primers, the end of one of which is biotin labeled at the 5' end.. Twenty (20) cycles of amplification (30 seconds at 96°C, 1 minute at 57°C, 2 minutes at 72°C), followed by 10 minutes at 72°C, were performed in a PTC- 100 Thermal Cycler equipped with a mechanized lid (MJ Research; Watertown, MA). Post-PCR amplification product purification was performed using streptavidin magnetic beads (MPG ® Beads; CPG, Lincoln Park, NJ). After washing the beads twice with buffer 1 (3 M NaCl, 10 mM Tris-HCl, 1 mM EDTA, pH 7.5), 20 μl of buffer 1 was mixed with the PCR product for 10 minutes at room temperature and the mixture was added to the streptavidin beads. The beads were separated with a magnet, and washed once with buffer 2 (10 mM Tris, 1 mM EDTA, pH 8.0). They were then dried and resuspended in 3μl of buffer 3 (80% (v/v) formamide, 4 mM EDTA, 5% TAMRA- or ROX-tagged molecular size standard (PE-Applied Biosystems, Foster City CA). Following denaturation at 96°C for 3 minutes, samples were then loaded onto 5% polyacrylamide, 6M urea, 0.5 x TBE ultrathin gels and _electrophoresed on a proprietary Niagara ® gel electrophoresis system. PCR products were visualized by virtue of the fluorescent FAM label at the 5' end of one of the PCR primers. Fluorescence detection and streptavidin- biotin selection steps ensured that all detected fragments had been digested by both enzymes. The primary components of the Niagara ® gel electrophoresis system are an interchangeable horizontal ultrathin gel cassette mounted in a platform employing stationary laser excitation and a multi-color CCD imaging system. Each gel cassette may be loaded with a total of 48 lanes (4 cycles of 12 wide) directly from a 96-well plate using a Beckman Biomek 2000 ® robotic arm (Beckman, Sunnyvale, CA). The Niagara electrophoresis system has the advantage of high throughput, with separation of fragments between 30 and 450 bases in 45 minutes. Niagara ® Gel Interpretation ® The output from the Niagara ® gel electrophoresis system was processed using the Java- based, internet-ready Open Genome Initiative (OGI) software suite. Gel images were initially visually checked for quality and lane tracking. Each lane contained the FAM-labeled products of a single GeneCalling ® reaction plus a molecular weight "sizing-ladder" spanning the range from 50 to 500 bp. The ladder peaks provided a correlation between camera frames (collected at 1 Hz) and DNA fragment size in base pairs (bp). Following tracking, the lanes were extracted and the peaks in the sizing ladder were ascertained. Linear interpolation between the ladder peaks was utilized to convert the fluorescence traces from frames to base pairs. A final quality control (QC) step checked for various anomalies (e.g., low signal-to-noise ratio, poor peak resolution, missing ladder peaks, and lane-to-lane sample bleeding). Data which passed all of the aforementioned criteria were submitted as point-by-point length versus amplitude addresses to an Oracle 8 database for subsequent difference identification. Difference Identification For each restriction enzyme pair (subsequence) comprising each sample set, a composite trace was calculated. This composite trace calculation entailed compiling all of the individual sample replicates (typically 3), followed by application of a scaling algorithm for best-fit to normalize the traces of the experimental set versus that of the control set. The scaled traces were then compared on a point-by-point basis to define areas of amplitude difference which meet the minimum, pre-specified threshold for a statistically-significant difference. Once a region of difference was characterized, the local maximum for the corresponding traces of each set was identified. The variance of the difference was determined by: σ _ ( y) = λ l { j ) 2 a 2 lolal ( j: S l ) + λ 2 ( 7 ) 2 σ )„ l j- S 1 ) where λ,(j) and λ 2 (j) represents scaling factors and (j:S) represents the trace composite values over multiple samples. The probability that the difference was statistically significant was calculated by: where y is the relative intensity. All difference peaks were stored as unique database addresses in the specified expression difference analysis. Northern Blot Analysis 1 μg of Poly (A) + RNA from 3 animals of each genotype was electrophoresed in agarose/formaldehyde gels, blotted to PVD-nylon filters and probed with fill-in oligonucleotides labeled with 2 P-dCTP. The hybridization was quantitated with a storage phosphor imaging plate using the Fuji BAS2000 ® . Blots were stripped and re-probed for Gadph to normalize gene expression levels. Induction levels are expressed as the ratio of average normalized hybridization signals. Radiation Hybrid Mapping A commercially-available, rat T55 radiation hybrid panel (Research Genetics; Huntsville, AL), consisting of 106 individual hybrids was utilized in this analysis. It was determined empirically that hybrid samples 1, 20, 35, 38, 60 and 90 had very low retention when compared to the other samples in the panel. In addition, a total of 94 rat hybrid (RH) samples was utilized, in order to efficiently perform PCR in a 96-well format (94 RH samples, plus negative and positive control). Accordingly, RH samples 1-100 from the T55 radiation hybrid panel, excluding the 6 low retention RH samples, previously discussed, were used. MapPairs ® simple sequence repeat (SSR) markers (Research Genetics) were utilized. All markers were run in duplicate and evaluated/scored as a pair. RH templates were distributed into 384 well PCR plates (MJ Research) at 20 ng/well using a Tecan Genesis 100 ® pipetting robot, and allowed to desiccate. PCR reactions were performed in 5 μl total volumes using the following concentrations of reagents: 0.5 μM each primer, 200 MM dNTPs, IX PC2 buffer (50 mM Tris-HCl pH 9.1, 16 mM ammonium sulfate, 3.5 mM MgCl,, 150 μg/ml BSA, IX Rediload (Research Genetics) and 0.25U KlenTaq ® (Clonetech Advantage; AB Peptides, Inc.). PCR amplification reaction conditions (Thermocycle) were as follows: initial 3 minute denaturation at 94°C; subsequent denaturation at 94° C for 30 seconds; initial annealing temperature of 65°C for 30 seconds; elongation at 68° C for 30 seconds; second cycle annealing temperature of 63°C for 30 seconds; all subsequent cycles, annealing temperature of 60°C for a total of 35 cycles. PCR products were then subjected to electrophoresis through a 3% agarose (BRL) gel using IX TBE buffer, for 30 min at 200V. Gel images were documented using an Alpha Innotech 950 ® imaging system. All markers were typed twice and discordant or ambiguous results were repeated. Data was compiled in a spreadsheet and analyzed using RHMAPPER (Stein et al. (1995) "RHMAPPER", unpublished software, Whitehead Institute / MIT Center for Genome Research. Available at http://www.genome.wi.mit.edu/ftp/pub/software/rhmapper/). Results and Discussion Identification of Genes Differentially Expressed in Spontaneously Hypertensive Rats Differential gene expression (DGE) was performed on abdominal adipose tissue, kidney/adrenal gland, heart, brain and liver mRNA of SHR and WKY rats. The DGE method used was GeneCalling ® as described above (see U. S. Patent No. 5,871,697) and in Shimkets, R. A. et al. (Differential Gene Expression Analysis by Transcript Profiling Coupled to a Gene Database Query. Nat Biotech 17, 798-803 (1999)). Between 62 and 1 19 GeneCalling ® reactions were performed, each with a unique pair of restriction enzymes, on each of 5 tissues of triplicate SHR, SHRSP and WKY rats. Results are shown in Table 1 , which provides total gene expression differences by genotype and organ. Table 1 Differential Gene Expression in SHRSP, SHR & WKY Rats * 1.5-fold cutoff used in determining number of differentially expressed gene fragments ♦ 2-fold cutoff used in determining number of differentially expressed gene fragments The larger number of reactions was performed on tissues with greater transcriptional complexity, such as brain, in order to assure adequate coverage of expressed sequences. The abundance of between 11583 (heart) and 36452 (brain) different gene fragments was measured (Table 1), representing coverage of approximately 85% of transcribed genes. By comparison of the abundance of each of the gene fragments in SHR and WKY rats, a list of genes potentially associated with hypertension, obesity and insulin resistance was identified. 108 (heart) to 383 (brain) gene fragments, representing 0.7% to 1.4% of those assayed, were altered in expression by more than 1.5-fold between the two strains (Table 1). The identity of each of these differentially expressed genes was decoded by finding the gene with matching restriction fragment length in the publicly available rat sequence database (see FIG. 1). Novel genes, corresponding to fragments without a match in this database, were isolated and sequenced. Independent confirmation of gene expression difference by northern blot and/or competitive PCR was obtained for 92 gene fragments, representing 58 genes (since several genes were assayed more than once [Tables 1 & 2]). Table 2 illustrates differential gene expression between the SHR and WKY rats. Differential gene expression across a total of five tissues is illustrated, where a "+" indicates increased mRNA abundance in the SHR and a "-" indicates a decreased mRNA abundance in the SHR. The chromosome to which the gene maps is shown and a "*" denotes that the gene maps to a position within a known QTL. In addition, amino acid residue substitutions which were identified by the present invention are also provided, where applicable. Table 2: Gene Expression Differences Between SHR & WKY Rats ♦ Chromosomal location; Locations in italics determined in the present study by RH mapping *Chromosomal location overlaps with SHR QTL tNumbers indicate protein function: (1 ) Secreted Protein, (2) Structural. (3) Enzyme. (4) Transporter. (5) Receptor. (6) Other. Representative GeneCalling ® chromatograms are shown in FIGS. 1-2. Northern blot analyses were done to confirm expression results, and are described below. 15 of the 58 genes, or their encoded proteins, had been shown in previous studies to differ in expression or activity between SHR and control strains, demonstrating the validity of GeneCalling ® for DGE. Several of the differentially expressed genes in kidney /adrenal gland are excellent candidates for hypertension or insulin resistance causality. Two of these, steroid 21-hydroxylase (Cyp21) and 3-β-hydroxysteroid dehydrogenase (Hsdb3), encode steroid synthesis enzymes whose absence can lead to hypotension through inadequate aldosterone synthesis and excessive sodium excretion (CYP21 deficiency; Jospe, et al. 1987. Biochem. Biophys. Res. Commun. 142, 798-804), OMIM 201910, and HSDB3 deficiency, OMIM 201810, respectively. Hsdb3 was increased 85-fold in SHR kidney/adrenal gland, while Cyp21 was increased 4.4-fold (Table 2, FIG. 1). These changes may be anticipated to increase adrenal corticoid synthesis, possibly resulting in the salt retention and hypertension observed in SHR rats. In support of this hypothesis is the syndrome of apparent mineralocorticoid excess, type 2 (OMIM 207765), in which a defect in the related 11-β-hydroxysteroid dehydrogenase gene results in increased corticoid synthesis and hypertension. The expression of several other enzymes involved in steroid metabolism was also modulated in SHR kidney/adrenal gland, including 15-hydroxyprostaglandin dehydrogenase, the major enzyme of prostaglandin degradation, and 20-α-hydroxysteroid dehydrogenase. While defects in these genes have not been associated with a human disorder, the observed increase in expression of all of these enzymes in the SHR may also be anticipated to cause alterations in mineralocorticoid and glucocorticoid production that may be important from a blood-pressure or insulin-responsiveness standpoint. In this regard, it should be noted that other features of human CYP21 deficiency are hypoglycemia and obesity (Cornean, R. E., Hindmarsh, P. C. & Brook, C. G. 1998. Obesity in 21-hydroxylase deficient patients. Arch. Dis. Child lS, 261-263). Three transporters (sodium-glucose transporter [Sglt2] (Table 2 and FIG. 2), organic anion transport protein NKT, and aquaporin-3 [Aqp3]) were modulated in SHR kidney. Deficiency of aquaporin-2 (Aqp2), a water channel closely related to Aqp3, causes renal diabetes insipidus (OMIM 125800). While Aqp2 is differentially expressed in a rat congestive heart failure model (Nielsen et al. 1997. Proc. Natl Acad. Sci. USA 94, 5450-5455), Aqp3 is a thirst- responsive renal channel that functions in osmotically driven water reabsorption (Ecelbarger et al. 1995. Am. J. Physiol. 269, F663-F672). Increased expression of Aqp3 in SHR kidney may potentially increase water reabsorption leading to volume expansion and hypertension. Two enzymes catalyzing conversion of L-kynurenine to kynurenic acid, kynurenine aminotransferase (Kat) and kynurenine/α-aminoadipate aminotransferase (Aadat) were altered in SHR tissues (see below). Nine secreted proteins were differentially expressed in SHR, including two complement components (Clqβ and C3) and three protease inhibitors (kallistatin, contrapsin-related, and proteinase inhibitor α-I-III). Anf, which modulates blood pressure, and insulin-like growth factor- 1, which affects insulin levels, were modestly changed in expression in heart and liver, respectively. Three genes involved in fatty acid transport (Cd36, Apob, and the low molecular weight fatty acid binding protein) were modulated in SHR adipose. Increased expression of the cardiac isoform of fatty acid binding protein (FABP-H) in the SHR adipocytes suggests a role for this member of the FABP family in insulin resistance, since variants in related FABPs have been linked to obesity, dyslipidemia and insulin resistance (Hotamisligil, G. S., et al. 1996. Science 274, 1377-1379; Baier, L. J., et al. 1995. J. Clin. Invest. 95, 1281-1287). While the cDNA sequence of this gene was identical in the SHR and WKY rats, the differing levels of mRNA detected may affect protein levels contributing to the SHR insulin resistant phenotype. Most of the gene expression differences between SHR and WKY were tissue specific, suggesting that different genes may be associated with each of the SHR-specific disease traits (Table 2). One housekeeping gene, α-soluble NSF attachment protein (α-SNAP), was of interest because its abundance was modulated in all tissues studied, suggesting generalized alteration in its gene expression. Since α-SNAP is known to be involved in the translocation of the major insulin-responsive glucose transporter GLUT4 to the cell surface, this striking decrease in expression may explain part of the mechanism of insulin resistance in the SHR. Identification of Differentially Expressed Genes in SHRSP rats DGE was also performed on heart, brain and kidney mRNA of SHRSP and SHR using GeneCalling ® . Between 57 (kidney) and 115 (brain) GeneCalling ® reactions were performed, each with a unique pair of restriction enzymes, on each tissue of triplicate SHR and WKY rats (Table 1) permitting measurement of the abundance of 7488 (kidney) to 35739 (brain) different gene fragments (Table 1). Comparison of the abundance of each of the gene fragments in SHRSP and SHR rats identified 24 (heart) to 150 (brain) gene fragments (or 0.2% to 0.5% of the genes assayed) that were altered in expression by more than 1.5-fold (Table 1) and that may potentially be associated with stroke. The identity of each of these genes was determined, and independent confirmation of the expression difference by northern blot and/or competitive PCR was obtained for 33 gene fragments, representing 26 genes (Tables 1 and 3). Table 3 presents differential gene expression between the SHR-SP and SHR rats. Differential gene expression across a total of five tissues is presented, where a "+" indicates increased mRNA abundance in the SHR-SP and a "-" indicates a decreased mRNA abundance in the SHR-SP. The chromosome to which the gene maps is provided and a "*" denotes that the gene maps to a position within a known QTL. In addition, amino acid residue substitutions which were identified by the present invention are also provided, where applicable. Table 3 • Gene Expression Differences Between SHRSP and SHR Rats ♦Positive value = in SHRSP ND: not determined Novel: no significant BLASTN match to known gene ♦ Chromosomal location *Chromosomal location overlaps with SHRSP QTL tNumbers indicate protein function: ( 1 ) Secreted Protein. (2) Structural. (3) Lnzyme. (4) Transporter. (5) Other. Representative GeneCalling ® chromatograms are shown in FIG. 2. Northern blot analyses were done to confirm expression results, and are described below. Only 2 of the 26 genes (Anf and α cardiac myosin heavy chain) had been shown in previous studies to differ in expression between SHRSP and control strains (Kim et αl. 1996. Br. J. Pharmacol 118. 549-56). Among the known genes modulated in SHRSP brain were 2 glycolysis enzymes [β-β- enolase and aldolase A (Aldoa)], suggesting altered glucose metabolism in SHRSP brain. Interestingly, cystatin C (Cst3), previously shown to be mutated in cerebral amyloid angiopathy (OMIM 105150; Ghiso, et al. 1986. Proc. Natl. Acad. Sci. USA 83, 2974-2978), a disorder with a high incidence of hemorrhagic stroke, was increased in the SHRSP brain. While the human mutation does not alter the ability of cystatin C to inhibit proteinases, it does permit dimerization and aggregation that leads to amyloid deposition. Against a role for Cst3 in SHRSP stroke, however, is the absence of amyloidosis in SHRSP brains. Mapping of Differentially Expressed Genes The chromosomal location of differentially expressed candidate genes was determined using a rat radiation hybrid panel that had been typed for over 1600 genetic markers (Steen. R. G. et al. A high-density integrated genetic linkage and radiation hybrid map of the laboratory rat. Gen. Res. (in press at the time filing)). Following genotyping of candidate genes, map positions were constructed using RHMAPPER. Examples of mapped genes are shown (FIG. 3, Tables 2 and 3). Map locations of the differentially expressed genes were compared to previously reported stroke, hypertension, insulin resistance and obesity QTLs. Of 34 differentially expressed genes whose chromosomal location was determined, 7 mapped within the support interval of a previously described QTL (FIG. 3, Tables 2 and 3): Kat mapped within an SHR hypertension QTL on Chr 3; Cd36 mapped within coincident SHR insulin resistance, hypertension, and hypertriglyceridemia QTLs at the telomere of Chr 4; Sglt2 and Aldoa mapped near the Sa locus on Chr 1 within support intervals for hypertension and stroke QTLs (Gu et al. 1996. J Clin. Invest. 97, 777-788; Rubattu et al. 1996. Nat. Genet. 13, 429-434); n/mapped on Chr 5 within an SHRSP QTL for increased stroke latency (Rubattu et al. (1996)); and the Chr 20 major histocompatibility complex (MHC) class I genes, LW2 and α chain, mapped within an SHR hypertension QTL (FIG. 3, Tables 2 and 3). Candidate Gene Mutation Detection 14 differentially expressed genes that mapped within the support intervals of QTLs were examined for cDNA sequence variation in SHRSP, SHR and WKY strains. Nonconservative amino acid substitutions were found in 5 of the genes (Aldoa, Kat, Cd36, Sglt2, and Anf) that may contribute to stroke, hypertension and insulin resistance in SHRSP and SHR rats (Tables 3 and 4; FIG. 4). Cd36 Cd36 expression was found to be significantly reduced in SHR heart and adipose tissue (FIG 2C). In addition, Cd36 mapped within the SHR QTL for insulin resistance related to glucose uptake and hypertriglyceridemia (FIG. 3B). The fatty acid transport protein (FAT)/CD36 homolog was found to contain numerous amino acid substitutions. The amino acid sequence of the regions at amino acid residues 148-191 and 213-257 of the FAT/CD36 variant in SHR-SP, SHR, WKY and human possessing the amino acid substitution is shown in FIG. 4 (SEQ ID NO: 10-13) and (SEQ ID NO: 14-17), respectively. This result was also found by Aitman et al. (Nat. Genet. 21, 76-83 (1999)), who identified Cd36 as a candidate gene for SHR insulin resistance QTLs on the basis of DGE and RH mapping using a different DGE approach. The multiple sequence variants in SHR Cd36 were found to be the result of unequal genomic recombination of a duplicated ancestral Cd36 gene (Aitman et al (1999)). In addition, this group demonstrated absence of CD36 protein in the plasma membrane of SHR heart and adipose tissue, and found CD36 overexpression in transgenic mice to result in lowering of blood triglycerides and fatty acids. The association between the SHR CD36 allele and insulin resistance in the rat suggests an important function of this receptor, and the finding of a corresponding linkage of NIDDM in humans to a potentially syntenic region of Chr 7q suggests that CD36 may play a causal role in insulin resistance in humans as well. This association of Cd36 with diabetes has not previously been established. In this regard, the inventors have found that levels of Cd36 expression in the Goto-Kakizaki rat, a model for Type II, or non-insulin dependent, diabetes is 20-fold higher than in normal rats. These observations suggest the use of probes that are diagnostic for the Cd36 mRNA or for expression of CD36 protein as a means of assessing whether a subject is predisposed for type II diabetes. This gene and gene product may also serve as targets for therapeutic intervention to counter a predisposition to type II diabetes or treat subjects diagnosed as having type II diabetes or who are obese. In addition to plasma membrane fatty acid binding and import, Cd36 functions as a platelet adhesion molecule, binding thrombospondin and collagen. CD36 mutation in humans leads to a defect in platelet-collagen adhesion (Frieda, S., Pearce, A., Wu, J. & Silverstein, R.L. 1995. J. Biol. Chem. 270, 2981-2986; Rigotti, A., Acton, S.L. & Krieger, M. 1995. J. Biol. Chem. 270, 16221-16224; Ibrahimi, A., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 2646-2651; Diaz-Ricart, M., et al. 1996. Arterioscler. Thromb. Vase. Biol 16, 883-888). Interestingly in this regard, the SHRSP Cd36 gene codes for additional amino acid variation from the SHR and maps near an SHRSP Chr 4 stroke protective locus (Rubattu, S., et al. (1996)), suggesting the possibility of Cd36 involvement in the stroke phenotype as well. Sodium-glucose co-transporter, Sglt2 Sglt2 was decreased in abundance in SHR kidney (FIG. 2B), and was mapped within an SHR hypertension QTL (FIG. 3 A). It was found to contain a nonconservative substitution of a highly conserved amino acid (L638Q; FIG. 4). The amino acid sequence of the region possessing the amino acid substitution of the SGLT2 variant (L638Q) in SHR, WKY, human, rabbit and pig is shown in FIG. 4 (SEQ ID NOs: 1 -5). This finding suggests that variation in Sglt2 may be directly involved in hypertension in SHR rats. Activating mutations affecting selectivity, stoichiometry or activation state may increase sodium reabsorption, leading to plasma volume expansion and concomitant hypertension. Similarly, increased glucose reabsorption through this transporter enzyme, might lead to increased plasma glucose. Interestingly, inhibitors of sodium- glucose co-transporters have been used in preclinical studies as euglycemic agents in diabetes mellitus (Tsujihara, K., et al. 1996. Chem. Pharm. Bull. (Tokyo) 44, 1 174-1180). Kynurenine aminotransferase, Kat Kat was increased in abundance in SHR and SHRSP kidney (FIG. 2A). It mapped within an SHRSP hypertension QTL (FIG. 3B), and the enzyme was found to contain an amino acid substitution (E27G; FIG. 4) that changes the charge of a residue that is conserved across all known /_αt-homologs from human to C. elegans. This suggests that variation in Kat may be directly involved in hypertension in the SHR. The amino acid sequence of the region possessing the amino acid substitution of the kynurenine aminotransferase variant (E27G) in SHR, WKY, human and nematode is shown in FIG. 4 (SEQ ID NO:6-9). Evidence that Kat-E21G differs functionally from the wild type comes from previous studies demonstrating greatly reduced Kat activity in SHR brain and kidney compared with WKY (Kapoor, V., Kapoor, R., & Chalmers, J. 1994. Clin. Exp. Pharmacol. Physiol. 21, 891- 896; Kapoor, V., Thuruthyil, S.J. & Human, B. 1998. Neuroreport 9, 1431-1434). Kat catalyzes the conversion of L-kynurenine to kynurenic acid, an endogenous antagonist of glutamatergic neurotransmission. Given the accumulating evidence of the importance of medullary glutamatergic pathways in the control of blood pressure, as well as the increased sensitivity of SHR cardiovascular neurons to glutamate, it seems plausible that Kat-E21G may play a role in the pathogenesis of hypertension in the SHR. In addition, there is some evidence that increased blood kynurenine levels are associated with refractory human hypertension (Rudzite, V.K., Vitols, AN., Liepinja, D.J. & Silava, A.K. 1990. Cor. Vasa. 32, 56-63). Reduced abundance of a second enzyme with kynurenine aminotransferase activity, Aadat, was observed in SHR adipose tissue and may also contribute to the previously reported reduction in KAT activity in SHR (Kapoor, V., Kapoor, R., & Chalmers, (1994); Kapoor, V., Thuruthyil, S.J. & Human, B. (1998)). In order to directly test the effects of kynurenic acid on_blood pressure in the SHR, 12 week old animals were dosed intravenously for 3 days with 2mg/kg of kynurenic acid (Sigma) and their blood pressure was measured by intraarterial occlusion. Animals dosed with kynurenic acid (n=23) showed a significant increase in systolic (30mmHg, p=0.083) and diastolic blood pressure (33.2mmHg, p=0.027) without a significant change in heart rate, body weight or blood glucose levels relative to vehicle-dosed SHR (n=23). This is the first direct evidence that kynurenic acid can affect blood pressure, and the expression of kynurenine aminotransferase primarily in the kidney and brain suggests that this pathway may be involved in a feedback mechanism of blood pressure regulation from the kidney to the brain. This effect of kynurenic acid also suggests that inhibitors of the production of this compound, stimulators of its breakdown or competitors of its action, presumably on NMDA or other amino acid receptors may be potential therapeutic avenues for the regulation of blood pressure in humans. Based on these findings, the genes in the kynurenine pathway may also be excellent candidate genes for human hypertension. These results indicate that hypotension can be treated by administering kynurenic acid to such a hypotensive subject. They also implicate the importance of inhibiting the activity of KAT in a subject whose blood pressure is higher than normal. In order to identify such an inhibitor, the present invention includes a method of screening for an inhibitor of KAT activity by contacting a preparation of KAT with a putative KAT inhibitor and detecting an actual inhibitor as a substance that succeeds in inhibiting the activity. The results above also suggest a role for a blood pressure related glutamatergic receptor which may be inhibitable by an antagonist; in a favorable case such an antagonist is related to kynurenic acid. A screening method to identify such a substance involves contacting a preparation of brain glutamatergic receptors with a putative antagonist and identifying as a lead any substance that binds specifically to the receptor. Anf Previous studies have suggested Anf to be a plausible candidate gene for stroke susceptibility in SHRSP rats. For example, ANF levels are elevated in stroke patients (Estrada V, et al. 1994. Am. J. Hypertens. 7, 1085-1089), and administration of exogenous ANF attenuates cerebral edema in acute stroke (Rosenberg, G.A. & Estrada, E.Y. 1995. Stroke 26, 874-877). Reduction of Anf expression leads to salt-sensitive hypertension in a dose-dependent manner in mice (John, S.W., et al 1995. Science 267, 679-681). Anf is known to map close to SHRSP QTLs that engender both increased stroke latency and increased infarct size on rat Chr 5 (Rubattu, S., et al. (1996); Jeffs, B., et al. 1997. Nat Genet 16, 364-367). These findings suggest a novel, blood pressure-independent role in stroke predisposition for the peptide hormones encoded by this gene. Expression of Anf w s found to be increased in SHRSP heart (FIGS. 2E and 2F), in agreement with previous studies showing Anf expression and ANP levels to be augmented in SHRSP ventricles compared with SHR or WKY, both prior to hypertension at 6 weeks of age, and in established hypertension with ventricular hypertrophy (Arai, H., et α/.1988. Circ. Res. 62, 926-930). Furthermore, immunocytochemical studies have shown the distribution of expression of ANP in ventricular myocytes of SHRSP to be much greater than in those of WKY rats (Nishimura, T., Mizukawa, K., Nakao, K., Yamada, H., Kinoshita, M. & Ochi, J. 1994. Arch. Histol Cytol 57, 1-7). The vasorelaxant effect of exogenously administered ANF in internal carotid arteries has also been shown to be less in SHRSP than SHR or WKY rats (Russo, R., et α/.1998. J Hypertens. 16, 151-156). Sequencing of the Anf cDN A from SHRSP, SHR and WKY rats revealed 13 sequence changes in SHRSP. GeneCalling ® (FIG. 2E) also directly identified one of these, a 2-bp deletion in the 3' UTR. A single SHRSP sequence variant was identified that was predicted to change a highly conserved amino acid within the prohormone, pro ANF. The variant gene had a G to T substitution at nucleotide 363 (relative to sequence X00665), that was predicted to result in replacement of a conserved glycine at position 75 with a serine residue (FIG. 4D). The amino acid sequence of the region possessing the amino acid substitution of the prepronatriodilatin variant in SHR-SP, SHR, WKY, human, pig and horse is shown in FIG. 4 (SEQ ID NO:26-31). G75S does not alter the composition of α ANF (ANF 99-126), the peptide with potent natriuretic activity. It may, however, affect cleavage of αANF from pro ANF (ANF 1-126), since the conformation of pro ANF has been shown essential for the specific ANF-endoproteinase to act with fidelity (Rangaraju & Harris, 1991. Arch. Biochem. Biophys. 290, 418-426). Further studies will be necessary to delineate the role of Anf-Gl 5S in SHRSP stroke latency and size. Interestingly, ANF appears to have therapeutic efficacy in the treatment of stroke in a different rat model of diet-induced stroke (Lin, et αl, 1999. Hypertension 33, 219-224). AldoA AldoA exhibited significant reduction in expression in all SHRSP tissues examined (FIG. 2D), colocalized with a stroke predisposition QTL on Chr 1 , and was found to contain a methionine to valine substitution near the amino terminus (FIG. 4D). The substituted methionine is completely conserved in all species examined, including 12 mammalian species. While serum and cerebrospinal fluid aldolase A activity measurements have found use as a prognostic marker in stroke, hitherto there has not been evidence that AldoA may be directly involved. Aldolase A was demonstrated to map to the stroke predisposition locus on chromosome 1 and possessed a methionine (Met) to valine (Val) amino acid substitution near the protein's amino terminus. It should be noted that the amino acid sequence of aldolase A is extremely conserved throughout numerous genus and species. The amino acid sequence of the region possessing the amino acid substitution of the aldolase A variant in SHR-SP, SHR, WKY, mouse, human, seal, dog and rabbit is shown in FIG. 4 (SEQ ID NO: 18-25). The finding of differential expression and amino acid substitution in the extremely conserved aldolase A gene, as well as its coincident location near a region of stroke predisposition, suggests that this enzyme (whose activity has long been known to be elevated in the sera of patients with cerebro vascular insult) may play a direct role in the onset of the cerebrovascular event. The amino acid residue which is substituted in the SHR-SP has been demonstrated to be completely conserved in every organisms from which it has been sequenced, including at least 12 mammals. While aldolase A is a well-characterized, glucose-induced glycolytic enzyme, it has also been shown to bind α-tubulin, whose mRNA accumulates after transient ischemic brain insult (see e.g., Volker & Knull, 1997. Arch. Biochem. Biophys. 338(2):237-243 . Breakdown of the cytoskeleton has been proposed to be a central event in the evolution of ischemic brain damage. In addition, an amino acid substitution (S340T) was found in α-tubulin in the SHR and SHR-SP, relative to the amino acid sequence of the protein in both WKY control rodents and literature-reported sequences. This evidence suggests the possible involvement of aldolase A and α-tubulin in predisposition to vascular injury. Similarly, the amino acid sequence of the region possessing the amino acid substitution of the α-cardiac myosin variant in SHR-SP, SHR, WKY, mouse and human is shown in FIG. 4 (SEQ ID NO:32-36) and the amino acid sequence of the region possessing the amino acid substitution of the α-tubulin variant in SHR, WKY, mouse, chicken, human and fluke is shown in FIG. 4 (SEQ ID NO:37-42). The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims. Various publication are cited herein, the disclosures of which are incorporated by reference in their entireties. EQUIVALENTS From the foregoing detailed description of the specific embodiments of the invention, it should be apparent that unique methods for the rapid identification of the genes responsible for quantitative trait loci and compositions identified thereby have been described. Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims which follow. In particular, it is contemplated by the inventor that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims.

Claims: WHAT IS CLAIMED IS: 1. An isolated protein comprising an amino acid sequence at least 80% identical to a protein selected from the group consisting of an SGLT2 protein including the amino acid sequence RQE, a kynurenine aminotransferase protein including the amino acid sequence substitution E27G compared a wild-type kynurenine aminotransferase, a FAT/CD36 protein having one or more of the amino acid substitutions shown in FIG. 4C, an aldolase A protein including the amino acid sequence EVI, a prepronatriodilatin protein including the amino acid sequence RSP, an α-cardiac myosin comprising the amino acid sequence KAK, and an α- tubulin protein comprising the amino acid sequence RSI, or a fragment or derivative of one of said proteins. 2. The isolated protein of claim 1, wherein said protein comprises any of the amino acid sequences of (SEQ ID NOs:l-42). 3. The isolated protein of claim 1, wherein said protein possessrd a longer biological half life in vivo, relative to the corresponding, native human proteins. 4. An antibody which is specific for, and possesses the ability to bind to, the protein of claim 1. 5. An isolated nucleic acid sequence encoding the protein of claim 1. 6. An antibody which is specific for, and possesses the ability to bind to, the nucleic acid sequence of claim 5. 7. An isolated anti-sense nucleic acid derivative of the nucleic acid of claim 5. 8. An antibody which us specific for, and possesses the ability to bind to, the anti- sense nucleic acid derivative of claim 7. 9. A method of treating or preventing hypertension, said method comprising " administering to a subject in which such treatment or prevention is desired an amount of a therapeutic selected from the group consisting of: the protein of claim 1 , the antibody of claim 4, the nucleic acid of claim 5, and the anti-sense nucleic acid derivative of claim 7, wherein said therapeutic is administered in an amount sufficient to treat or prevent hypertension in said subject. 10. A method of decreasing or preventing diabetes or insulin resistivity, said method comprising administering to a subject in which such treatment or prevention is desired an amount of a therapeutic selected from the group consisting of the protein of claim 1 , the antibody of claim 4, the nucleic acid of claim 5, and the anti-sense nucleic acid derivative of claim 7, wherein said therapeutic is administered in an amount sufficient to treat or prevent diabetes or insulin resistivity in said subject. 11. A method of treating or preventing obesity or dyslipidemia, said method comprising administering to a subject in which such treatment or prevention is desired an amount of a therapeutic selected from the group consisting of: the protein of claim 1 , the antibody of claim 4, the nucleic acid of claim 5, and the anti-sense nucleic acid derivative of claim 7, wherein said therapeutic is administered in an amount sufficient to treat or prevent obesity or dyslipidemia in said subject. 12. A method of treating or preventing or delaying a stroke in a subject, said method comprising administering to a subject in which such treatment or prevention is desired an amount of a therapeutic selected from the group consisting of the protein of claim 1 , the antibody of claim 4, the nucleic acid of claim 5, and the anti-sense nucleic acid derivative of claim 7, wherein said therapeutic is administered in an amount sufficient to treat or prevent sufficient to treat or prevent or delay stroke. 13. The method of claim 12, wherein said stroke is ischemic stroke. 14. The method of claim 12, wherein said therapeutic increases latency to stroke in stroke-prone rats fed a high salt diet. 15. The method of claim 14, wherein said therapeutic is a protein comprising the amino acid sequence of SEQ ID NO:26-31. 16. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a therapeutic selected from the group consisting of the protein of claim 1 , the antibody of claim 4, the nucleic acid of claim 5, and the anti-sense nucleic acid derivative of claim 7, and a pharmaceutically acceptable carrier. 17. A kit comprising in one or more containers, a therapeutically or prophylactically effective amount of the pharmaceutical composition of claim 16. 18. The use of a therapeutic in the manufacture of a medicament for treating a syndrome asssociated with human metabolic syndrome X, wherein said therapeutic is the protein of claim 1, the antibody of claim 4, the nucleic acid of claim 5, the antibody of claim 6, the anti- sense nucleic acid derivative of claim 7, or the antibody of claim 8.. 18. A method for screening for an allele protective against hypertension, diabetes, obesity and/or stroke in a subject comprising detecting a mutant allele selected from the group consisting of the SGLT2 allele, a mutant kynurenine aminotransferase allele, a mutant FAT/CD36 allele, a mutant aldolase A allele, a mutant prepronatriodilatin allele, a mutant α- cardiac myosin allele, and a mutant α-tubulin allele, the presence of said mutant allele being indicative of an allele protective for hypertension, diabetes, obesity and/or stroke. 19. The method of claim 18, wherein said mutant allele encodes a polypeptide comprising the amino acid sequence of any of SEQ ID NOs:l, 6, 10, 11, 14, 15, 18, 26, 32, and 37. 20. A method for screening for a modulator of latency or predisposition to hypertension, diabetes, obesity and/or stroke, said method comprising: (a) administering a putative modulator of activity of a test protein to a test animal prone to hypertension, diabetes, obesity and/or stroke, wherein said test protein is selected from the group consisting of SGLT2, kynurenine aminotransferase, FAT/CD36, aldolase A, prepronatriodilatin, α-cardiac myosin and α-tubulin; and (b) measuring one or more physiological parameters associated with activity of said test protein, wherein a change in one or more parameters relative to an animal not administered the putative modulator indicates that the putative modulator modulates latency or predisposition to hypertension, diabetes, obesity and/or stroke. 21. The method of claim 20, wherein said test animal is a recombinant test animal which expresses a test protein transgene or expresses said transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein said promoter is not the native gene promoter of said transgene. 22. A method for screening for an allele protective against hypertension, diabetes, obesity, or stroke in a subject, said method comprising detecting a mutant allele selected from the group consisting of a mutant nucleic acid selected from the group consisting of the SGLT2, kynurenine aminotransferase, FAT/CD36, aldolase A, prepronatriodilatin, α-cardiac myosin and α-tubulin protein genes; wherein said allele is indicative of an allele protective for hypertension, diabetes, obesity, or stroke. 23. A method for screening for a modulator of activity or of latency or predisposition to hypertension, diabetes, obesity or stroke, said method comprising: administering a test compound to a test animal at increased risk for hypertension, diabetes, obesity or stroke, wherein said test animal recombinantly expresses a SGLT2, kynurenine aminotransferase, FAT/CD36, aldolase A, prepronatriodilatin, α-cardiac myosin or α -tubulin protein; measuring expression the activity of said protein in said test animal; measuring the activity of said protein in a control animal which recombinantly expresses said protein and is not at increased risk for at risk for hypertension, diabetes, obesity or stroke; and comparing expression of said protein in said test animal and said control animal, wherein a change in the activity of said protein in said test animal relative to said control animal indicates the test compound is a modulator of latency of hypertension, diabetes, obesity and/or stroke. 24. A recombinant, non-human animal possessing a mutant gene encoding a mutant protein, wherein said gene is the SGLT2, kynurenine aminotransferase, FAT/CD36, aldolase A, prepronatriodilatin, α-cardiac myosin and α-tubulin, and wherein said gene is under the control of a promoter which is not the native promoter of said mutant gene, and further wherein said mutant gene encodes a mutant protein which either increases the latency or decreases the predisposition to hypertension, diabetes, obesity and/or stroke. 25. A recombinant, non-human animal which is the product of a process comprising introducing a nucleic acid into said non-human animal, or an ancestor thereof, said nucleic acid comprising a mutant gene sequence selected from the group consisting of the SGLT2, kynurenine aminotransferase, FAT/CD36, aldolase A, prepronatriodilatin, α-cardiac myosin and α-tubulin gene. 26. A recombinant, non-human animal possessing a mutant gene selected from the group consisting of the SGLT2, kynurenine aminotransferase, FAT/CD36, aldolase A, prepronatriodilatin, α-cardiac myosin and α-tubulin genes, said gene being under the control of a promoter which is not the native promoter of said gene, wherein said gene encodes a mutant gene product which either increases the latency or decreases the predisposition to hypertension, diabetes, obesity and/or stroke. 27. A method of assessing predisposition to type II diabetes in a subject, said method comprising: a) providing a first nucleic acid that hybridizes specifically with a nucleic acid whose sequence encodes CD36 or a fragment thereof; b) contacting the first nucleic acid with a second nucleic acid obtained from the subject; and c) measuring the binding of the first and second nucleic acids; wherein binding above a predetermined value indicates that the subject is predisposed to type II diabetes. 28. A method of assessing predisposition to type II diabetes in a subject, said method comprising: a) providing an antibody that binds immunospecifically to CD36 or an epitope thereof; b) contacting a sample obtained from the subject with the antibody; and c) measuring the binding of the antibody to a component of said sample; wherein binding above a predetermined value indicates that the subject is predisposed to type II diabetes. 29. A method of inhibiting type II diabetes in a subject, said method comprising administering to the subject an amount of a nucleic acid that hybridizes specifically with a nucleic acid whose sequence encodes CD36 or a fragment thereof in an amount effective to inhibit the development of type II diabetes in said subject.

Inventors: SHIMKETS RICHARD A, SHIMKETS, RICHARD, A.
Applicants: CURAGEN CORP, SHIMKETS RICHARD A, CURAGEN CORPORATION, SHIMKETS, RICHARD, A.
Application year: 1999
Main classification: C12N15
IPC codes: A01K67, A61K31, A61K38, A61K39, A61K48, A61P3, A61P9, A61P43, C07K14, C07K16, C12N9, C12N15, C12Q1, G01N33